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I SUMMARY 
Epstein-Barr virus (EBV) is one of eight known human herpesviruses and belongs to 
the γ-herpesvirus subfamily. EBV is extremely successful by infecting >90% of the adult 
human population. Most of its success can be attributed to its default state of infection, called 
latency. Latent EBV infection is characterized by very limited viral gene expression patterns, 
resulting in a maximum level of immune evasion. Latent EBV infection is tightly associated 
with various lymphoid and epithelial cell malignancies such as Burkitt’s lymphoma and 
nasopharyngeal carcinoma. EBV is transmitted via saliva to the next susceptible host and 
establishes a life long persistent infection within the host´s B cell pool. Since EBV is an orally 
transmitted virus, the pharyngeal cavities are the portal of entry and exit for EBV. Thus, the 
epithelium, lining the pharyngeal, cavities is an important barrier that EBV has to overcome 
to complete its life cycle. 
Within this thesis, I investigated different aspects of the EBV infection in epithelial 
cells. I assessed the impact of increased telomerase activity, achieved by ectopic expression of 
hTERT and the impact of Toll-like receptor (TLR) 9 activation on the EBV infection in 
epithelial cells. Increased telomerase activity is characteristic for stem and progenitor cells 
within the basal layers of epithelial tissues and a hallmark of cancer in general. It was shown 
that increased telomerase activity facilitates the establishment of an EBV infection in 
epithelial cells by promoting expression of latent EBV genes and therefore contributing to 
EBV maintenance in epithelial cells. TLRs are part of the innate immune system and are the 
first line of defense against invading microorganisms. There was no significant impact of 
TLR9 activation on the EBV infection in the employed epithelial model cell lines observed. 
Nevertheless, our data contributes to the hypothesis that TLR activation in epithelial cells 
might trigger or support lytic EBV reactivation and thus facilitating EBV transmission. 
In summary, the results of this work suggest that hTERT might facilitate an EBV-
driven malignant transformation of epithelial cells and indicate that EBV might actually 
benefit from an activated innate immune system in epithelial cells. In conclusion, this data 
emphasizes the need for further evaluation of hTERT expression/activity inhibitors and TLR 
agonists as potential treatment strategies to fight EBV-associated epithelial malignancies. 	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II ZUSAMMENFASSUNG 
Epstein-Barr-Virus (EBV) ist eines von acht bekannten humanen Herpesviren und 
gehört zur Unterfamilie der γ-Herpesviren. Die Tatsache, dass >90 % der erwachsenen 
Bevölkerung mit dem Virus infiziert ist, macht EBV zu einem außerordentlich erfolgreichen 
Virus. Den größten Anteil am Erfolg von EBV kann der so genannten Latenz, dem Standard 
Zustand der Infektion, zugeschrieben werden. Eine latente EBV-Infektion ist gekennzeichnet 
durch sehr limitierte Expressionsmuster viraler Gene was zu einem Höchstmaß an 
Immunevasion führt und eng mit verschiedenen bösartigen B-Zell- und Epithelzell-Tumoren, 
wie dem Burkitt-Lymphom und dem Nasophyrynxkarzinom, verknüpft ist. EBV wird durch 
Speichel auf den nächsten Wirt übertragen und etabliert dann eine lebenslang persistierende 
Infektion innerhalb des B-Zell-Pools des Wirtes. Da EBV oral übertragen wird, stellt der 
Rachenraum das Ein- und Austrittsportal für EBV dar. Somit ist das Epithel des Rachenraums 
eine wichtige Barriere für EBV, die es für das Virus zu überwinden gilt um dessen 
Lebenszyklus zu vervollständigen. 
Im Rahmen dieser Arbeit untersuchte ich verschiedene Aspekte der EBV-Infektion in 
Epithelzellen. Ich überprüfte die Auswirkungen einer erhöhten Telomerase-Aktivität, erzielt 
durch die ektopische Expression von hTERT, und die Wirkung von Toll-like Rezeptor (TLR) 
9-Aktivierung auf die EBV-Infektion von Epithelzellen. Gesteigerte Telomerase-Aktivität ist 
charakteristisch für Stamm- und Vorläuferzellen in den basalen Schichten von 
Epithelgeweben und im Allgemeinen ein Merkmal von Krebs. Es zeigte sich, dass eine 
erhöhte Aktivität der Telomerase die Etablierung einer EBV-Infektion in Epithelzellen, durch 
Förderung der EBV Latenz-Genexpression, erleichtert und somit zur Erhaltung von EBV in 
Epithelzellen beiträgt. TLRs gehören zum angeborenen Immunsystem und sind somit Teil der 
ersten Verteidigungslinie gegen eindringende Mikroorganismen. Bei der Untersuchung der 
Modell Epithelzelllinien konnte ich keinen signifikanten Einfluss der Aktivierung von TLR9 
auf die EBV-Infektion feststellen. Dennoch tragen unsere Daten zur Hypothese bei, dass 
TLR-Aktivierung in Epithelzellen eine lytische EBV-Reaktivierung auslösen oder 
unterstützen könnte und somit die Übertragung von EBV erleichtert. 
Zusammenfassend zeigen die Ergebnisse dieser Arbeit, dass hTERT eine EBV-
getriebene, maligne Transformation von Epithelzellen fördern könnte und deuten darauf hin, 
dass EBV tatsächlich von einem aktivierten, angeborenen Immunsystem in Epithelzellen 
ZUSAMMENFASSUNG 	  
	  
3 
profitieren könnte. Abschließend unterstreichen diese Daten die Notwendigkeit weiterer, 
grundlegender Untersuchungen zur Eignung von hTERT Expressions-/Aktivitäts-Inhibitoren 
und TLR-Agonisten als mögliche Behandlungsstrategien zur Bekämpfung EBV-assoziierter 
Epithelzell-Tumoren. 	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III INTRODUCTION 
III.1 Epstein-Barr virus 
Epstein-Barr virus (EBV) is one of eight members of the herpesviridea family that 
commonly infect humans. EBV belongs to the subfamily of γ-herpesviruses and its tissue 
tropism in vivo is mainly restricted to B lymphocytes and epithelial cells (Table 1). EBV is an 
enveloped virus with a linear, double-stranded DNA genome of about 184 kbp (1). The virus 
is usually transmitted via saliva and is enormously successful in infecting humans since more 
than 90% of the adult human population is seropositive for immunoglobulin G against the 
viral capsid antigen (VCA) complex of EBV (2, 3). In developing countries, primary infection 
by EBV occurs early during childhood and the course of infection is usually asymptomatic or 
displays unspecific symptoms. If seroconversion is delayed to adolescence or adulthood more 
than 70% of the patients develop the most frequent clinical manifestation of a primary EBV 
infection, called infectious mononucleosis (IM) or kissing disease (4). IM is a self-limiting 
disease that goes along with typical clinical symptoms, such as pharyngitis, fever, fatigue, 
cervical lymphadenopathy, hepatosplenomegaly and T cell lymphocytosis. Like all 
herpesviruses, EBV can infect cells in a latent or a lytic form (1, 5). Upon primary infection, 
EBV persists life long in latent state within the host memory B cell pool (6). The switch from 
latent to lytic infection is tightly controlled by various mechanisms (7) and is under 
investigation as potential treatment strategy against EBV-associated malignancies. The latent 
EBV infection is characterized by very restricted gene expression patterns, thus leading to a 
maximum level of immune evasion (5, 8–11). By contrast, lytic EBV replication, or so-called 
productive infection, results in generation of infectious progeny virus particles and is 
therefore important for virus transmission from cell to cell and host to host (1, 5). 	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Table 1: Human herpesvirus Taxonomy, nomenclature and main tissue tropisms (adapted from (12)). 
Trivial name (and 
acronym) 
Formal name (and 
acronym) 
Herpesvirus 
subfamily; genus 
Primary target 
cells 
Main site of 
latency 
Herpes simplex virus-1 
(HSV-1) 
Human herpesvirus 1 
(HHV-1) 
Alpha; 
Simplexvirus Mucoepithelia 
Sensory and 
cranial nerve 
ganglia 
Herpes simplex virus-2 
(HSV-2) 
Human herpesvirus 2 
(HHV-2) 
Alpha; 
Simplexvirus Mucoepithelia 
Sensory and 
cranial nerve 
ganglia 
Varizella-zoster virus 
(VZV) 
Human herpesvirus 3 
(HHV-3) 
Alpha, 
Varicellovirus Mucoepithelia 
Sensory and 
cranial nerve 
ganglia 
Epstein-Barr virus 
(EBV) 
Human herpesvirus 4 
(HHV-4) 
Gamma; 
Lymphocryptovirus 
B and epithelial 
cells 
Memory B 
cells 
Human 
cytomegalovirus 
(HCMV; CMV) 
Human herpesvirus 5 
(HHV-5) 
Beta; 
Cytomegalovirus 
Epithelia, 
Endothelia, 
Monocytes and 
lymphocytes 
Monocytes, 
Lymphocytes 
Roseola virus (HHV-
6A/-6B) 
Human herpesvirus 6A 
and 6B (HHV-6/-6B) Beta; Roseolovirus T cells 
Various 
leukocytes 
Roseola virus (HHV-7) Human herpesvirus 7 (HHV-7) Beta; Roseolovirus T cells 
T cells, 
epithelia 
Kaposi’s sarcoma-
associated herpesvirus 
(KSHV) 
Human herpesvirus 8 
(HHV-8) 
Gamma; 
Rhadinovirus 
Probably 
lymphocytes and 
epithelia 
B cells 
 
III.2 EBV and associated malignancies 
EBV was the first human γ-herpesvirus discovered by Anthony M. Epstein, Bert G. 
Achong and Yvonne M. Barr (13). The virus was originally detected in cultured lymphoma 
cells from tumor samples, collected in Uganda by Dennis Burkitt, a British colonial surgeon. 
Epstein and Barr assumed a “passenger role” for the virus, since it persisted in vitro in 
dividing cells for many weeks (13) but it turned out that they found the first human virus with 
tumorigenic potential. This was soon confirmed by in vitro experiments, e.g. by the capability 
of EBV to transform B lymphocytes into lymphoblastoid cell lines (LCLs) with infinite 
proliferation capacity, supporting the potential role of EBV as an oncogenic virus (14). Based 
on specific criteria to establish a causal relation (15), such as I) elevated antibody titers to the 
virus prior to tumor development; II) presence of the viral genome within tumor but not in 
associated/adjacent normal cells; III) clonal nature of the viral genome; and IV) expression of 
viral genes in tumor cells, and due to its tissue tropism, it is not surprising that EBV was 
subsequently linked to various lymphoid and epithlelial cell malignancies (Table 2). Apart 
from Burkitt’s lymphoma (BL) (16), EBV has been associated with Hodgkin’s lymphoma 
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(HL) (17, 18), post-transplant lymphoproliferative disorder (PTLD) (19–22), nasopharyngeal 
carcinoma (NPC) (23–30) and a subset of gastric carcinomas (GC) (31–35) and several others 
as mentioned elswhere (5, 36, 37). EBV owes its oncogenic potential the latent infection 
cycle, whereas distinct latency programs with specific EBV gene expression patterns were 
characterized in vivo and in vitro (Table 2). 
The oncogenic role of EBV in epithelial cell malignancies has been most extensively 
studied for NPC and GC. Aspects of EBV-associated NPC and GC and their oncogenesis are 
discussed and reviewed elsewhere (5, 24, 26, 31, 33, 38–40). The following sections will 
briefly summarize characteristics of EBV-associated NPC and GC with focus on common 
features and differences regarding oncogenesis and the causal role of EBV. 
 
Table 2: EBV associated malignancies and characteristic latent gene expression patterns (adapted from 
(5)). AIDS = acquired immunodeficiency syndrome; UCNT = undifferentiated carcinomas of the 
nasopharyngeal type; VAHS = virus-associated hemophagocytic syndrome; EBERs = EBV-encoded RNAs; 
EBNA = Epstein-Barr nuclear antigen; LMP = latent membrane protein; a = intermediate latency type with 
variable levels of LMP expression (41); b = latency type I and 40% of the cases show LMP2 expression (42); c = 
latency pattern follows type II with LMP1 expression restricted to few cells (43). 
Tumor Subtype Association with EBV [%] 
Latent EBV genes 
expressed 
Type of 
latency 
Burkitt’s Lymphoma 
Endemic 100 
EBERs, EBNA1 I Sporadic >20 
AIDS-associated 30-40 
Hodgkin’s lymphoma 
Mixed cell; lymphocyte 
depletd 60-80 EBERs, EBNA1, 
LMP1, LMP2 II Nodular sclerosing 20-40 
Post-transplant 
lymphoproliferative 
disease 
Immunodefficient 100 EBERs, EBNA1, 2, 
3A, 3B, 3C, LP, 
LMP1, LMP2 
III Post-transplant >90 
AIDS-associated >80 
Nasopharyngeal 
carcinoma 
Undifferentiated, non-
keratinizing 100 EBERs, EBNA1, 
(LMP1)a, LMP2a I/II
 a Undifferentiated, 
keratinizing 30-100 
Gastric carcinoma 
UCNT 100 EBERs, EBNA1, 
(LMP2)b I
 b; (II) 
Adenocarcinoma 5-15 
NK/T cell lymphoma 
VAHS-associated 100 EBERs, EBNA1, 
(LMP1)c, LMP2 II
 c; (I) 
Nasal 100 
Leiomyosarcoma 
Immunodefficient 100 (EBERs, EBNA1, 
EBNA2, LMP1, 
LMP2) (44) 
(Type III 
suggested) 
(44) 
Post-transplant 100 
AIDS-associated 100 
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III.2.1 EBV-associated NPC and GC 
Pathology, incidence of EBV-associated NPC and GC 
NPC usually presents as a neck mass or with symptoms of nasal obstructions and the 
loss of hearing and arises from the surface epithelium mainly of the lateral and superior walls 
of the nasopharynx. Due to its moderate early symptoms, NPC is rarely diagnosed before the 
age of 30 and male are disproportionately affected (2-3 male/female). According to the World 
Health Organization (WHO) NPC are classified into three types depending on their 
differentiation status and histology (45): keratinizing squamous cell carcinomas (WHO type I) 
that are highly differentiated with characteristic epithelial growth patterns and keratin 
expression; differentiated non-keratinizing carcinomas (WHO type II) with retained epithelial 
cell shape and growth patterns; and undifferentiated carcinomas (WHO type III) without 
keratin expression and indistinct growth pattern with intense infiltration of lymphoid cells 
referred to as lymphoepithelioma or lymphoepithelial carcinoma. Of all NPC cases about 20% 
are of the type I while the remaining 80% are type II and III NPCs. Type II and III NPCs are 
distinct from all other squamous cell carcinomas because of the universal association with 
EBV and are therefore also referred as EBV-associated NPCs. In most countries, NPC is a 
rare malignant disease with an age-adjusted incidence rate for both sexes of less than 1 per 
100,000 (46). The disease is very common in southern China, especially among the Cantonese 
population of the Guangdong province, and Southeast Asia. In Hong Kong, an incidence rate 
of 20-30 per 100,000 and 15-20 per 100,000 among men and women, respectively, was 
reported for NPC (38) but with decreasing trend (~30%) (47). The incidence rate of NPC 
drops to 2-3 per 100,000 among men of the northernmost Chinese provinces (38). 
Additionally, an increased incidence of EBV-associated NPCs was identified among Arabs of 
North Africa and the Inuit population of Alaska and Greenland (38, 48). Interestingly, NPC is 
more frequently found among southern Chinese emigrants and less common among Chinese 
born in North America than those born in southern China (49, 50). This distinct geographical 
and ethnical distribution pattern strongly suggests an involvement of two etiological factors, 
genetic susceptibility and environmental factors, in the development of NPC in addition to 
EBV. 
Similar to NPC, the majority of EBV-associated GCs (EBVaGCs) (~80%) are of the 
lymphoepithelioma type with a diffuse, poorly differentiated histology and dense infiltration 
of lymphoid cells. EBVaGCs are also described as undifferentiated carcinomas of the 
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nasopharyngeal type (UCNT). Macroscopically, EBVaGC often presents as an ulcerated or 
saucer-like tumor accompanied by marked thickening of the gastric wall (31, 51, 52). 
Thereby, the proximal stomach, the cardia and the middle stomach, are predisposed site for 
the development of EBVaGC (31, 39, 40, 53, 54). Whereas gastric cancer associated with 
Helicobacter pylori, causing chronic gastritis, intestinal metaplasia, and cancer, 
predominantly arises in the antrum part of the stomach. Thus, this pathogen might cause 
gastric cancer by independent mechanisms (31, 39). EBVaGC is, in contrast to BL and NPC 
that are endemic in equatorial Africa and southern China, respectively, a non-endemic 
malignant disease with a worldwide distribution. The incidence rates for EBVaGC differ 
regionally between 20.1% in Japan and 1.3% in Papua New Guinea (40). Recent meta-
analysis showed that the prevalence of EBV was similar in cases from Asia (8.3%), Europe 
(9.2%), and America (9.9%), thus about 80,000 patients are estimated to develop EBVaGC 
(54). As with NPC, a predominance of EBVaGC in males was confirmed by meta-analysis 
(53, 54) and mostly younger individuals appear to be affected (53) although the age-
association remains inconclusive (31, 39, 40). 
Etiological factors apart from EBV 
An association of the Human Leukocyte Antigen (HLA) alleles/haplotypes and the 
development NPC was consistently reported in many studies as reviewed elsewhere (24, 55). 
Especially HLA class I alleles, mostly of HLA-A and HLA-B subtypes specifically those 
prevalent within the Chinese but not in the Caucasian population, show a strong correlation 
with NPC and other EBV-associated malignancies (24, 55). Additionally, other genetic factor 
like chromosomal aberration and epigenetic changes seem to be crucial for NPC initiation and 
development as extensively reviewed elsewhere (26). Several studies showed numerical and 
structural abnormalities, e.g. deletions, duplications, translocations and rearrangements, 
leading to loss of heterozygosity (LOH) in the NPC genome (26). The most common genetic 
alterations in NPC are allelic deletions on chromosomes 3p and 9p (56–58). In NPC, LOH is 
often associated with inactivation of tumor suppressor genes like p16 (CDKN2A), Ras 
Association Domain Family 1A (RASSF1A) and activation of oncogenes such as Cyclin D1 
(CCND1), lymphotoxin-beta receptor (LTBR), phosphatidylinositol 3-kinase (PI3K), 
NOTCH3, leading to deregulation of associated signaling pathways (26). The cell cycle 
regulators p16, inactivating cyclin D1/cdk4/pRb axis and inhibits cell cycle progression from 
G1- to S-phase, and cyclin D1, regulating G1- to S-phase transition, seem to play a pivotal 
role in NPC development. Activity of p16 is lost in more than 85% of NPCs, while CCND1 is 
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overexpressed in over 90% of the cases (26). Both features appear to be important for the 
establishment and the support of a stable EBV infection in nasopharyngeal epithelial cells 
(59–61). Epigenetic modifications, like promoter hypermethylation and histone acetylation, 
are additional mechanisms to regulate gene expression and are frequently detected in NPC 
(26). 
EBVaGC show as well specific genetic and epigenetic alterations. However, data on 
chromosomal aberrations is rare and inconsistent. It was reported that gains in chromosome 
11 and losses in 15q15 are more common in EBVaGC (62, 63), while zur Hausen et al. 
reported a significantly more frequent loss of chromosome 4p and of 11p that was exclusively 
restricted to EBVaGC (64). Epigenetic abnormalities, as already describes for NPC, are 
considered as key mechanisms promoting carcinogenesis of EBVaGC (33). Hypermethylation 
of CpG islands, leading to transcriptional silencing of tumor suppressor genes, are global and 
non-random in EBVaGC (33). In particular, a number of genes, such as p16, p14 
(CDK2AP2), p73 (TP73), E-cadherin (CDH1), RASSF1A are frequently hypermethylated in 
EBVaGC (33, 40). 
Besides the genetic factors, some environmental factors are correlated with NPC. The 
most prominent correlation is the association with the traditional diet of the southern Chinese 
population. Especially, Cantonese-style salted fish and other preserved foods contain volatile 
nitrosamines, serving as chemical carcinogens that may induce genetic damage in 
nasopharyngeal epithelial cells (24). The consumption of salted fish during childhood was 
shown to be related to an increased risk of NPC in southern China (38). The decreasing 
incidence rate in Hong Kong may be attributed to changes in life style, in particular the 
avoidance of salted fish in the diet of young children (24). However, there is only a weak or 
controversial association of NPC with other environmental factors like cigarette smoking and 
formaldehyde exposure (38). 
Like with NPC several environmental factors are discussed in the context of EBVaGC. 
An interview study from Japan showed a significant correlation between frequent intake of 
salty food and an increased risk for EBVaGC (65). Other dietary factors like coffee drinking 
and high-temperature drinks as well as frequent exposure to wood dust and/or iron filings, 
which may induce mechanical injuries in the stomach membrane, correlated with an increased 
risk for EBVaGC, although not significantly (65). 
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III.2.2 EBV and the association with NPC and GC 
The first link to NPC was established in 1974 by Klein and colleagues (66). They 
found EBV DNA in anaplastic cells of tumor biopsies from poorly differentiated 
nasopharyngeal carcinoma. These observations were confirmed by Anderson et al. in 1977 
(67). Already in 1966, a correlation between EBV and NPC was suggested based on 
serological data, showing increased EBV antibody titer in sera of NPC patients (68). This was 
followed by the detection of EBV DNA in tumor biopsies from anaplastic carcinomas of the 
nasopharynx (69). Finally, the monoclonality of the EBV genome, based on the detection of 
terminal repetitive sequences by southern blot, was proven and the clonal expansion of a 
single EBV-infected progenitor cell was suggested as model for EBV associated epithelia cell 
malignancies (70). By contrast to NPC, the association of EBV with GC was recognized 
almost 20 years later. The first report about the detection of EBV DNA by polymerase chain 
reaction (PCR) in lymphoepithelioma-like carcinomas of the stomach was published in 1990 
(71). In 1991, Shibata et al. (72) detected monoclonal EBV by PCR and in situ hybridization 
(ISH) of GC biopsies. Subsequently, EBV was correlated with an average of about 10% of all 
gastric cancers worldwide (39, 52, 53, 73, 74), while the frequency of EBV positive GC 
varied from country to country. This subset was then defined as EBVaGC. Interestingly, EBV 
alone does not transform epithelial cells in vitro and low-grade dysplastic precursor lesions in 
both NPC and EBVaGC have been shown to be EBV negative (32, 57, 58). This leads to 
more or less similar multistep models for the carcinogenesis of NPC and potentially as well 
for EBVaGC. These models suggest that preexisting cellular alterations generate cells that are 
either more susceptible to EBV infection or are able to support a persistent latent EBV 
infection, thus contributing to tumor progression and malignant transformation (24–27, 75) 
(Figure 1). 	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III.2.3 EBV and its contribution to NPC and GC development 
As mentioned above, EBV alone is not able to transform epithelial cells and the 
oncogenic potential of EBV is attributed to the latent EBV infection. Thus, EBV infection is 
considered as a late event in NPC and EBVaGC development (compare Figure 1). Latent 
EBV infection shows distinct gene expression patterns in NPC and EBVaGC (compare Table 
2). NPC displays in general a type II latency pattern with expression of Epstein-Barr nuclear 
antigen 1 (EBNA1), the latent membrane proteins 1 and 2 (LMP1 and LMP2), EBV-encoded 
RNAs (EBERs) and several BamHI A rightward transcripts (BARTs) including the lytic 
protein BARF1. However, the expression of the LMPs is variable (41). By contrast, EBVaGC 
shows an even more restricted expression pattern, reflecting latency type I with expression of 
EBNA1, EBERs and BARTs (including BARF1). Additionally, about 40% of all cases show 
expression of LMP2 (42). Key functions of the latency-associated EBV genes involved in 
NPC and EBVaGC are summarized in Table 3 and will be discussed in more detail within the 
following sections.   
Figure 1: Multi-step tumorigenesis model for Epstein-Barr virus-associated epithelial malignancies such 
as nasopharyngeal carcinoma (NPC) and gastric carcinoma (GC). EBV infection alone cannot drive 
malignant transformation of normal, healthy epithelial cells in vitro. The healthy epithelium might harbor cells 
that are already susceptible to an infection by EBV or cells might become susceptible after induction of pre-
malignant genetic and epigenetic alterations such as loss of heterozygosity (LOH), inactivation of tumor 
supressor genes and activation of oncogenes. These low-grade pre-invasive lesions, possibly a result of inherited 
genetic traits, environmental/dietary factors and inflammation, respectively, might support and facilitate the 
establishment of a latent EBV infection. The expression of latent EBV gene products leads to clonal expansion 
of infected cells and promotes malignant transformation. Upon carcinoma development, carcinoma cells might 
acquire further genetic and epigenetic alterations, leading to metastatic phenotype and therefore to invasive 
carcinoma. 
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Table 3: Key functions of latency-associated EBV encoded RNAs and proteins involved in NPC and 
EBVaGC. EBERs = EBV encoded RNAs; BARTs = BamHI A rightward transcripts, including the open reading 
frame (ORF) for BARF1 and additional putatively protein encoding ORFs; EBNA = Epstein-Barr nuclear 
antigen; LMP = latent membrane protein. 
Latent EBV product Key functions Reviewed in 
EBERs Growth promotion; induction of type I interferons and pro-inflammatory cytokines (76, 77) 
BARTs Maintenance of viral latency; resistance to apoptosis; immune evasion; oncogenesis (76–80) 
EBNA1 Maintenance of the viral episomal genome; growth promotion; metastasis promotion; immune evasion (81) 
LMP1 
Growth promotion and cell cycle progression; resistance to apoptosis; 
promotion of invasion and metastasis; immune evasion; modulation 
of the tumor environment 
(41, 75, 82) 
LMP2 Maintenance of viral latency; suppression of cell differentiation; promotion of metastasis (41, 83–85) 
 
EBV-encoded RNAs (EBERs) 
EBV encodes two small non-coding RNAs, EBER1 and EBER2, that are abundantly 
expressed (up to 107 molecules per cell) in each latently EBV-infected cell (1). Thus, EBER 
in situ hybridization (EBER-ISH) is a powerful tool to identify EBV-associated malignancies 
and is commonly used for diagnostics. EBERs were found to induce expression and secretion 
of insulin-like growth factor 1 (IGF-1) in vitro (86, 87). IGF-1 acts as autocrine growth signal 
and EBERs are therefore suggested to contribute cancer development and tumor growth via 
IGF-1 in vivo, since IGF-1 is constantly expressed in NPC biopsies and GC-derived cells 
express the IGF-1 receptor (76, 87). Additionally, EBERs can modulate the innate immunity. 
It was shown that EBERs can be recognized by the retinoic acid inducible gene I (RIG-I) and 
by TLR3, in combination with the EBER-binding protein LA (lupus antigen). Recognition of 
EBER leads to the induction of type I interferon (IFN), interleukin 10 (IL-10) and pro-
inflammatory cytokines, respectively (88, 89). While IGF-1 and IL-10 can act as autocrine 
growth signals, the induction of type I IFNs and pro-inflammatory cytokine appears to be 
disadvantageous for EBV. However, EBERs confer resistance to IFN-induced, and Fas-
mediated apoptosis by blocking protein kinase R (PKR) phosphorylation (90) and pro-
inflammatory cytokine production might explain the high degree of lymphocyte infiltration in 
NPC and EBVaGC. 
BamHI A rightward transcripts (BARTs) 
The BamHI A region of the EBV genome contains a cluster of several transcripts 
called BARTs that are also abundantly expressed during EBV latency. BARTs are long, 
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multi-spliced transcripts that were originally discovered in cDNA libraries prepared from a 
serial passaged, xenografted NPC tumor (91). Differential splicing can produce several open 
reading frames (ORFs) putatively encoding for BARF0 and RK-BARF0, A73 and RPMS1. 
Although recombinant proteins with interesting functions could be generated from these 
ORFs in vitro, their biological relevance in vivo is questionable. None of them could be 
detected in tumors or EBV-infected cell lines (92, 93). However, recombinant BARF0 could 
be detected in vitro by immunoprecipitation using serum from NPC patients (94). An 
additional protein is encoded within the BamHI A region, called BARF1. BARF1 is 
commonly found in NPC and EBVaGC (95, 96) but is considered to be a lytic protein since it 
is expressed upon induction of the lytic cycle within BL cells (97). However, BARF1 shows 
tumorigenic activity. Expression of BARF1 can induce malignant transformation in rodent 
fibroblasts, can immortalize primary monkey epithelial cells and enhances tumorigenicity of 
BL and NPC derived cell lines as summarized by Takada (76). In addition to BARF1 induced 
cell cycle activation, BARF1 induced activation of Bcl-2 contributes to its transforming 
capacity (76). While BARF1 is abundantly expressed in NPC and EBVaGC, EBV-encoded 
micro RNAs (miRNAs), so called miR-BARTS, appear more important for EBV-driven 
epithelial cell malignancies (31, 78–80, 98). MiR-BARTs are closely related to siRNA and 
can regulate gene expression either by blocking protein synthesis or by induction of mRNA 
degradation (99). Currently, 22 EBV-encoded miRNA precursors (miR-BART1-miR-
BART22) are known to be expressed from two clusters within the BARTs and in principle 
can give rise to 44 mature miRNAs (78). MiR-BARTs are involved in regulation of both viral 
and host gene expression. The most important function of miR-BARTs is potentially 
maintenance of EBV latency, since EBV is believed to undergo lytic replication within 
oropharyngeal epithelial cells, which is also the reason why they are believed to be the source 
of infectious progeny virus (5, 100, 101). The miR-BART2-5p was shown to target BALF5 
(102), the viral DNA polymerase that is responsible for EBV-DNA replication during the lytic 
replication cycle, leading to suppression of the lytic cycle and EBV maintenance. Other viral 
targets of miR-BARTS are LMP1 (103–105), the major EBV oncogene, and LMP2A (106), 
the most immunogenic viral protein in latency I and II infections and involved in cellular 
transformation. MiR-BART-mediated fine-tuning of LMP1 expression balances its pro-
apoptotic and oncogenic effects and increases cellular proliferation, thus promoting cancer 
development. In contrast, down-regulation of LMP2A expression increases immune evasion. 
Additionally, most of the EBV-encoded miRNAs target host cell genes involved in apoptosis, 
immune recognition and tumor suppression as summarized by Lung et al. (79). Taken 
INTRODUCTION 	  
 
14 
together, miR-BARTs are important for EBV maintenance, immune evasion, prevention of 
apoptosis and oncogenesis in EBV-associated epithelial cell malignancies (79).  
Epstein-Barr Nuclear Antigen 1 (EBNA1) 
EBNA1 plays multiple important roles and is expressed in all proliferating latently 
EBV-infected cells (81). The main function of EBNA1 is maintenance of the EBV episome 
and its mitotic segregation to the daughter cells (107, 108). EBNA1 binds as dimer to specific 
elements, family of repeats (FR) and dyad symmetry (DS) elements, within the EBV oriP and 
ensures episomal replication once per cell cycle (109, 110). Additionally, EBNA1 can act as 
transcriptional activator for the LMP genes (111). Expression of EBNA1 alone was shown to 
increase primary tumor and metastasis formation by NPC cells and enhanced tumorigenicity 
of GC cells (112, 113). Several signaling pathways, known to regulate cell growth and 
transformation, are as well affected by EBNA1 (81). For example, EBNA1 was shown to 
disrupt Promyelocytic leukemia (PML) nuclear bodies and modulate p53 levels in NPC and 
GC cells (114, 115), leading to resistance against p53-mediated and DNA-damage induced 
apoptosis, thus promoting cell survival. Interestingly, EBNA1 contains a glycine-alanine 
repeat sequence that serves as an inhibitor of HLA-I restricted antigen presentation and 
processing, hence leading to immune evasion (116). 
Latent Membrane Protein 1 (LMP1) 
LMP1 is considered the major oncogene of EBV since it has strong transforming 
properties in cultured cell lines and is one of five key viral proteins for B-cell transformation 
(41, 84). However, LMP1 is not expressed in EBVaGC while LMP1 transcripts are found in a 
majority of NPCs, although protein expression is detected only in 20-60% of the NPC tumors 
and amongst those sometimes only a small subset of cells show LMP1 protein expression (34, 
117, 118). Nevertheless, LMP1 can engage multiple signaling pathways contributing to cell 
proliferation, survival, motility and invasion. The function of LMP1 is strongly dependent its 
expression levels (75, 119, 120). The oncogenic properties of LMP1 are thereby mostly 
attributed to its function as constitutively active tumor necrosis factor (TNFR), by mimicking 
TNFR1 and CD40, in a ligand independent manner (41, 75, 82). LMP1 is an integral 
transmembrane protein and self-aggregation or oligomerization, which is driven by the 
hydrophobic transmembrane (TM) domains, is essential to activate intracellular signaling 
pathways (75, 82). TM domain mediated recruitment of the Rho-GTPase Cdc42 leads to 
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cytoskeletal remodeling and induction of signaling pathways involved in cell proliferation and 
autophagy (121). The most profound effects of LMP1 are mediated by the C-terminal 
cytosolic tail, which contains 3 functional domains termed C-terminal activating regions 1-3 
(CTAR1-3). CTAR1-3 possess specific docking sites for signaling adaptor proteins, including 
the tumor necrosis factor receptor (TNFR)-associated factors (TRAFs), TNFR-associated 
death domain (TRADD), receptor interacting protein kinase (RIP), BS69 and Janus kinase 
(JAK)-3 proteins (41, 82, 85). This results in signal transduction through the nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB), through c-Jun N-terminal kinase 
(JNK)/p38-Stress-activated protein kinases (SAPK), through Phosphatidylinositol 3 kinases 
(PI3K)/Akt, through extracellular-signal-regulated kinase (ERK)-Mitogen-activated protein 
kinase (MAPK) and through Janus kinase (JAK)/Signal Transducer and Activator of 
Transcription (STAT) pathways and through induction of specific genes that are involved 
with apoptosis, cell cycle progression, cell proliferation, immortalization, invasion, migration 
and modulation of the tumor environment (41, 82, 85). An important additional target of 
LMP1 is the epidermal growth factor receptor (EGFR) (122, 123). Thus, LMP1 is involved in 
a wealth of cellular processes, as reviewed in great detail elsewhere (41, 75, 82) and might be 
crucial at least in the early stages of NPC development (28) by contributing to tumor 
progression. Interestingly, LMP1 was found to induce telomerase activity (82, 124). 
Telomerase expression and activity is in general a hallmark of cancer (125, 126) and 
interestingly, basal epithelial stem and progenitor cells within the basal layers of epithelial 
tissues show increased telomerase activity (127–132) as discussed later. 
Latent Membrane Protein 2 (LMP2) 
The EBV gene LMP2 encodes for two distinct proteins, LMP2A and LMP2B. Both 
proteins are integral transmembrane proteins like LMP1. Although both proteins share 
common or overlapping features, LMP2A possesses almost exclusively signaling capabilities, 
while LMP2B was suggested to negatively regulate LMP2A-mediated signaling (133). It is 
now widely accepted that LMP2A regulates and promotes EBV latency by blocking B cell 
receptor (BCR) mediated signaling and lytic reactivation of EBV (134, 135). Additionally, 
LMP2A promotes proliferation and survival in B cells (136). Responsible for LMP2A 
mediated signaling are specific motifs at the N-terminal cytosolic tail (41). These motives 
contain numerous tyrosine residues that constitute functional immunoreceptor tyrosine-based 
activation motifs (ITAM) and proline/tyrosine (PY)-motifs, capable of recruiting several 
signaling molecules like the tyrosine kinase Lyn, Syk, and the ubiquitin ligases Nedd4/Itchy. 
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These molecules lead to the activation of several signaling pathways, e.g. the PI3K/Akt, the 
JNK/SAPK, the ERK-MAPK and the Wnt/β-catenin, which promote cell growth, inhibit 
apoptosis and differentiation, and contribute to cell transformation (41). Especially LMP2A-
activated PI3K/Akt signaling appears to be important in epithelial cells regarding tumor 
development (41, 85). It was shown that LMP2A can block cell differentiation, enhance cell 
adhesion and cell motility, induce transformation and anchorage-independent growth through 
PI3K/Akt activation (137–142). Notably in EBVaGC, LMP2A can induce STAT3-mediated 
up-regulation of DNA methyltransferase 1 (DNMT1), leading to promoter hypermethylation 
and silencing of tumor suppressor genes (83). 
Exosomes 
Interestingly, EBV can modulate the tumor environment by induced secretion of 
exosomes. Exosomes are small vesicles of unique size and shape, known to contain transfer 
and messenger RNAs as well as proteins and other molecules. Exosomes released from EBV-
infected cells can contain LMP1, EBERs and BARTs, thus impacting on surrounding cells by 
their described functions (75, 76, 78, 85) and contributing to immune evasion (11, 80). 
III.3 EBV infection mechanisms of B cells and epithelial cells  
Before EBV can develop its full oncogenic potential, it first has to infect an epithelial 
cell to drive malignant transformation, thus contributing to development and progression of 
tumors such as NPC and EBVaGC. While the steps involved in the infection of B cells are 
quite well studied and understood (143, 144), the attachment and entry mechanisms of EBV 
into epithelial cells still remain to be fully elucidated. 
III.3.1 Infection of B cells by EBV 
The infection of B cells by EBV is a multistep process (Figure 2), requiring 
endocytosis (143, 144). The first step is attachment of EBV to B cells mediated by the cellular 
complement receptor type 2 (CR2; also known as cluster of differentiation 21 or CD21) and 
the viral glycoprotein complex gp350/220 (encoded by BLLF1). Subsequently, the viral 
glycoprotein gp42 (encoded by BZLF2) binds to HLA class II molecules, which serve as co-
receptor on the B cell. Gp42 is noncovalently associated with the viral glycoprotein complex 
gHgL (also known as gp85/gp25 encoded by BXLF2/BKRF2) that is part of the viral core 
fusion machinery in addition to the glycoprotein gB (also known as gp110 encoded by 
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BALF4). Binding of gp42 to HLA-II molecules triggers fusion of the viral and the endosomal 
membrane and finally allows entry of the tegumented EBV capsid into the cytoplasm of the B 
cell (143, 144). Interestingly, an additional attachment receptor for EBV, CD35 (or CR1), was 
recently identified in a patient with genetic CR2 deficiency (145) and thus potentially leading 
to a broader spectrum of EBV-susceptible cells. 
 
 
III.3.2 Infection of epithelial cells by EBV 
In contrast, the infection of epithelial cells by EBV is more complicated. Epithelial 
cells might express low levels of CR2 in vitro (146) but which, or even whether, epithelial 
cells normally express CR2 in vivo remains uncertain. Thus EBV has to employ a different 
strategy to infect an epithelial cell (Figure 3). Currently, there are several different 
mechanisms for the infection of epithelial cells by EBV proposed (143). The fist CR2-
independent EBV entry mechanism into epithelial cells was demonstrated in 1992 by Sixbey 
et al. (147). EBV-specific polymeric immune globulin A (IgA), commonly present in saliva, 
could mediate endocytosis-transfer of EBV into epithelial cells by binding of the J (joining) 
chain to the secretory component (SC) protein. However, this mechanism might be 
particularly relevant for EBV entry from the basolateral site or for transcytosis of EBV 
through epithelial cells since the SC protein is usually present at the basolateral surface of 
epithelial cells (147, 148). As a second mechanism it was demonstrated that B cell-derived 
EBV can bind to CD21-negative epithelial cells directly via the gHgL complex of the core 
fusion machinery (149, 150). Although the underlying mechanism and the receptor on the 
epithelial cell were not determined and identified, respectively, these observations indicated 
the presence of an epithelial receptor for gHgL (referred as gHgLR; potentially integrin αVβ5, 
αVβ6 and αVβ8 as described below). The third, and probably the most intriguing mechanism, 
Figure 2: Multi-step model for the infection 
of B cells by EBV (from reference (143); 
adapted). I.) Binding of EBV via gp350/220 to 
CR2 on the B cell surface and triggering of 
endocytosis. II.) The potential flexibility of 
CR2 may allow the EBV to approach closer to 
the cell membrane, where gp42 can interact 
with HLA class II molecules. III.) Interaction 
of gp42 with HLA class II subsequently 
triggers the interaction of the core fusion 
machinery, gHgL and gB, with the endosomal 
membrane. IV.) Fusion of viral and endosomal 
membranes, which allows entry of the 
tegumented capsid into the cytoplasm.  
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involves integrins expressed on epithelial cells. Integrins are well-know virus attachment 
factors (151, 152). Tugizov and colleagues showed that the viral transmembrane protein 
BMRF2 can interact with epithelial cell integrins (153), mediating infection of these polarized 
oropharyngeal epithelial cells from the basolateral surface. Subsequent studies confirmed that 
the RGD-motif, present at the exposed loop of BMRF2, is a ligand for β1, α3, α5, and αV 
integrins and that BMRF2 can facilitate cell-to-cell spreading of EBV (154–156). 
Additionally, integrins appear to be involved in fusion of EBV with epithelial cells (144, 
157). It was shown that binding via the KGD-motif of gHgL to αVβ5, αVβ6 and αVβ8 can 
trigger membrane fusion in cell-based assays and that binding induces conformational 
changes of these integrins (158, 159). Interestingly, it was recently demonstrated that EBV 
could be transcytosed through polarized epithelial cells in both directions, from the apical to 
the basolateral surface and vice versa (160). This implicates another important alternative 
mechanism involved in the life cycle of EBV, independent of productive infection in 
epithelial cells. 
 
 
 
 
 
 
 
III.3.3 EBV infection and the interplay between epithelial cells and B cells 
Thus, EBV obviously employs different mechanisms to infect B cells and epithelial 
cells. The viral glycoprotein gp42 is necessarily involved in B cell infection. By contrast, 
gp42 is not essential for epithelial cell infection. Moreover, gp42 impedes infection of 
epithelial cells (161). Interestingly, EBV particles released from B lymphocytes show low 
levels of gp42 and are more infectious for epithelial cells, while virions made in epithelial 
cells possess high levels of gp42 and are better able to infect a B cells. This led to a concept 
Figure 3: Models for CR2-independent 
infections of epithelial cells by EBV (from 
reference (143); adapted). A: Entry via 
gHgL alone (less efficient). I./II.) EBV binds 
directly via gHgL to gHgLR (potentially 
integrins αVβ5, αVβ6, and αVβ8). (3) 
Binding triggers the interaction of the core 
fusion machinery, gHgL and gB, with the 
cell membrane. B: Attachment and entry via 
BMRF2 and gHgL. I.) BMRF2 interacts with 
α5β1 integrins. II.) gHgL interacts with 
gHgLR. III.) Binding triggers the interaction 
of the core fusion machinery with the cell 
membrane. Final step is the same for both 
mechanisms. IV.) Virus and cell membrane 
fusion leads to release of the tegumented 
EBV capsid into the cytoplasm. 
A 
B 
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where EBV shuttles between B cells and epithelial cells during its life cycle, thus undergoing 
a switch in cell tropism (143). This concept supports the role of pharyngeal epithelial cells in 
lytic EBV replication and release of infectious virus for transmission. Thus implicating that 
transmitted EBV virions, shed by epithelial cells, would need to infect B cells directly within 
the oro- and nasopharyngeal mucosa of the next susceptible host. For example, this could 
occur within the nasopharyngeal-associated lymphoid tissue (NALT), which is well known to 
be heavily infiltrated with lymphocytes. However, the infection of epithelial cells in vitro is 
difficult to achieve using cell free EBV. It was suggested that successful and efficient 
infections of epithelial cells could be achieved by using cell-to-cell contact and B-cell 
mediated transfer infection approaches (162, 163). Although the infection frequencies could 
be increased 103 to 104 fold compared to infections using cell free virus, this was not or only 
in part confirmed in other studies on primary epithelial cells (164, 165). The underlying 
mechanism still needs to be elucidated but the hypothesis is that binding of EBV to B cells, 
via the interaction of gp350 and CD21, induces conformational changes within the viral 
envelope, therefore leading to exposure of viral ligands, e.g. BMRF2 or gHgL, to an putative 
epithelial receptor such as integrins (25, 143, 163). This is supported by the finding that 
antibodies against the viral gp350/220 can actually facilitate the infection of epithelial cells 
(147, 148, 166). A subsequent study revealed that the so-called B cell-mediated transfer 
infection is restricted to the basolateral surface of polarized epithelial cells (167). However, 
this finding appears not to be in line with the previous results of Tugizov et al. (153), who 
showed efficient cell-to-cell contact infection at the apical surface of polarized epithelial cells, 
although they used infected lymphocytes and not virus-coated B cells. 
Taken together, the biology of EBV infection in epithelial cells, including the precise 
infection mechanisms of epithelial by EBV and the role of the epithelium within the life cycle 
of EBV remains puzzling. The significance of the epithelium in the life cycle of EBV will be 
addressed within the discussion section of this thesis and a putative role as transit route for the 
epithelium within the life cycle of EBV will be suggested. 
III.4 Epithelial barrier as portal of entry for microorganisms and EBV 
The fundamental role of any epithelia is to provide barriers between different 
compartments of the organism and to the outside environment. The fact that over 90% of 
infections occur at or through mucosal surfaces highlights the significance of epithelia as fist-
line of defense against invading pathogens (168). Especially the epithelia lining the 
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pharyngeal cavities play an important role as physical and mechanical barriers against various 
environmental stimuli and invading microorganisms such as bacteria, fungi and viruses. Since 
EBV is transmitted via saliva and enters the host through the oral route, the epithelia within 
the pharyngeal cavities are as well the portal of entry and exit for EBV. The nasopharyngeal 
and palatine tonsils can be considered as gatekeepers and scavengers within the pharyngeal 
cavities and are part of the NALT within the Waldeyer’s ring. They might represent the 
perfect target organs for EBV entry into the body since they are extensively infiltrated with 
lymphocytes (169, 170). In addition, NALT plays a crucial role in host defense against 
invading pathogens in the upper respiratory tract by serving as an interface between innate 
and adaptive immune responses (170). 
III.4.1 Epithelial tissue architecture within the pharyngeal cavities 
There are distinct epithelia within the pharyngeal cavities. Whereas some mucosal 
regions are covered by a keratinized epithelium resembling epidermis, other regions are lined 
by a non-keratinizing epithelium (171). Regions that are subjected to mechanical forces 
associated with mastication such as the gingiva and hard palate, posses a keratinizing 
epithelium. The remaining soft tissues of the pharyngeal cavity are covered with non-
keratinized, stratified squamous epithelia. The stratified squamous epithelium is a dynamic 
tissue of distinct multilayer architecture (132, 171) with various patterns of differentiation (or 
maturation) between the deepest cell layer (undifferentiated) and the surface (differentiated). 
Undifferentiated epithelial cells within the basal layer of the epithelium, the stratum basale, 
are attached to the basement membrane by integrin-containing focal adhesions and are most 
important for tissue homeostasis. The basement membrane separates the epithelium from the 
underlying lamina propria and ensures correct and directed migration and differentiation of 
the overlying epithelial cells towards the surface of the epithelium. Differentiation involves 
migration accompanied by a loss of integrin expression and an increase in cadherin-mediated 
adhesion via close intercellular tight junctions and desmosomes (171). These tight 
intracellular connections separate the apical from the basolateral cell surface regions and 
ensure establishment and maintenance of cell polarity (170), thus contributing to tissue 
integrity and barrier function. The lamina propria contains blood vessels, minor salivary 
glands, structural fibers, nerves, fibroblasts and other cells like lymphocytes and plasma cells 
(172). As mentioned already, the stratum basale harbors a small sub-population of epithelial 
stem cells, which can undergo mitotic division and give rise to transiently proliferating 
progenitor cells (132, 173). These cells then can generate daughter cells that migrate and 
INTRODUCTION 	  
	  
21 
differentiate through the stratum spinosum and stratum granulosum towards the epithelial 
surface, the stratum corneum. 
III.4.2 Telomerase and the epithelium 
Dividing cells face two problems: I) the chromosome end-protection and II) the 
chromosome end-replication. The ends of linear chromosomes, such as those in eukaryotes, 
must be distinguished from broken DNA ends that require repair. Additionally, the gradual 
loss of sequence information at the terminal end of chromosomes, owing to incomplete 
replication by DNA polymerases, must be prevented (174). These problems are solved by the 
ribonucleoprotein telomerase and associated telomeric proteins. Telomerase consists of the 
catalytically active telomerase reverse transcriptase (TERT) and the template-containing RNA 
component (TR or TERC). The main telomerase function is to ensure chromosomal 
maintenance in dividing cells by synthesizing and adding multiple tandem repeats of DNA, so 
called telomeric DNA, to the chromosomal ends. Additionally, recruited telomeric proteins 
further protect the linear chromosomal ends (174). Despite its main function in chromosomal 
maintenance, growing evidence suggest several additional, telomere-independent activities of 
TERT (175–177). TERT can act independently from TERC and its enzymatic activity and is 
involved in many biological processes, e.g. regulation of gene expression, promotion of cell 
proliferation, modulation of DNA-damage response, inhibition of apoptosis and 
inflammation, thus contributing to cancer development. For example, TERT can directly 
modulate NF-κB and Wnt-dependent gene transcription (178–180). Nevertheless, telomerase 
expression and activity ensure indefinite proliferation and self-renewal capacity and is usually 
restricted to stem and progenitor cells and is considered to be a hallmark of cancer in general 
(125, 126). 
As mentioned above, a small sub-population of epithelial cells residing on the 
basement membrane of epithelial tissues possesses stem cell characteristics, like indefinite 
proliferation and self-renewal capacity. These epithelial stem cells give rise to transiently 
proliferating cells that either reside within the stem cell compartment or migrate and 
differentiate towards the epithelial surface (173) and are therefore crucial for epithelial tissue 
homeostasis. The self-renewal capacity of these indefinitely proliferating cells is ensured by 
increased telomerase expression and activity, which is lost while the cells migrate and 
differentiate (127–132). Additionally, due to their self-renewal and proliferation capacity, the 
epithelial stem and progenitor cells are more likely to aquire genetic and epitgenetic 
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alterations during mitotic divisions (132), thus generating an environment facilitating an 
establishment of an EBV infection as disscussed above and in manuscript I. 
III.4.3 Telomerase and EBV 
To gain access to its preferred target cell for a persistent latent infection, the B cell, 
EBV has to overcome the epithelium. Therefore it is likely that EBV encounters epithelial 
cells with increased telomerase expression and activity. EBV was shown to preferentially 
infect differentiated epithelial cells obtained from the sphenoidal sinus (sECs), to replicate 
lytically in differentiated oropharyngeal and tonge epithelial cells and as well as in tonsillar 
plasma cells (164, 181–184), indicating a dependence of the EBV infection on the 
differentiation status of the cells. By contrast, latent EBV infection in epithelial cells is 
restricted to and associated with EBV-associated epithelial cell malignancies as discussed 
above. Recently, it was shown that telomerase-immortalized nasopharyngeal epithelial (NPE) 
cell clones are able to support a long-term infection by EBV (60, 185). Ectopic expression of 
human TERT (hTERT) in combination with LMP1 extended the life span of primary 
nasopharyngeal epithelial cells and contributed to their immortalization (185). Loss of p16 
activity and overexpression of CCD1, which putatively occurs prior to the infection by EBV, 
thereby appears to be crucial for the establishment and the support of a stable EBV infection 
(25) as discussed above. More recently, it was shown by Wille et al. that undifferentiated 
telomerase-immortalized normal oral keratinocytes (NOKs) supported a long-term latent EBV 
infection (186). Additionally, so far unpublished data from the same group apparently shows 
that a lytic EBV infection is preferentially found in more differentiated cell layers while 
undifferentiated basal layers of NOKs remain latently infected as mentioned elsewhere (7). 
However, it is not clear in which way an increased telomerase activity in epithelial 
cells might actually be beneficial for EBV. It is possible that epithelial cells with increased 
telomerase activity are more susceptible to an infection by EBV or that an increased 
telomerase activity might be required for EBV to establish an infection in epithelial cells. 
Moreover, it was shown that expression of hTERT inhibits lytic EBV replication and that 
hTERT silencing can trigger lytic EBV replication in B cells (124, 187, 188). 
III.4.4 Innate immunity and the epithelium 
The innate immune system represents the first line of defense against invading 
pathogens apart from the mechanical and physical barrier function of the epithelium. The 
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innate immunity is crucial for mounting a rapid response against various kinds of 
microorganisms that are potentially harmful and is responsible to prime and shape the 
subsequent adaptive immunity. Amongst others, the innate immune system comprises anti-
microbial effector molecules such as proteins, peptides, cytokines, chemokines and 
interferons as well as cellular receptor molecules and specific cell types like macrophages, 
dendritic cells, natural killer (NK) cells and others (189–193). As mentioned before, epithelial 
cells play a pivotal role for the innate immune system due to their strategic location at the 
border between the exterior environment and the interior of the body. Epithelial cells of the 
nasal and pharyngeal cavities can sense invading pathogens especially via a broad range of 
cell-surface and intracellular pattern recognition receptors (PRRs) such as Toll-like receptors 
(TLRs), C-type lectin receptors (CLRs), nucleotide-binding oligomerization domain (NOD)-
like receptors (NLRs) and retinoic acid-inducible gene 1 (RIG-I)-like receptors (RLRs) (189, 
191, 193). These PRRs recognize common, so called pathogen-associated molecular patterns 
(PAMPs) and binding of such PAMPs by PRRs triggers signaling pathways, leading to the 
expression of anti-microbial effecter molecules like pro-inflammatory cytokines, chemokines 
and interferons or triggers endocytosis as it is the case for CLRs. Nevertheless amongst these, 
TLRs were the first PRRs to be identified. They have been named after the Toll protein of the 
fruit fly (Drosophila melanogaster), which was originally described as important factor in 
embryonal dorso-ventral patterning (194) and subsequently found to be essential in the 
protection of fungal infections (195), indicating its contribution to innate immunity. Soon 
thereafter, the first human homologue was identified (196). Until today 10 human TLRs have 
been identified including their specific PAMPS or ligands except for TLR10 as summarized 
in Table 4. 
In summary, TLRs recognize PAMPS from a wide range of microbes such as viruses, 
bacteria, mycobacteria, fungi and parasites and can be divided into two groups according to 
their location within distinct cellular compartments. The first group, consisting of TLR1, 2, 4, 
5 and 6 is expressed in the plasma membrane at the cell surface and is involved in recognition 
of proteins, lipopeptides and polysaccharides. The second group comprises the nucleic acid 
sensors TLR3, 7, 8 and 9 that are exclusively located in intracellular vesicles such as the 
endosomes, endoplasmatic reticulum, lysosomes and endolysosomes (197). 	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Table 4: Toll-like receptors (TLRs) and their corresponding recognized pathogen-associated molecular 
patterns (PAMPs) and cellular location (adapted from (197, 198)). * = heterodimers. 
TLR Location PAMPs/ligands (source) 
1/2* Plasma membrane (cell surface) Triacyl lipopeptides (bacteria and mycobacteria) 
2 (1 or 6)* Plasma membrane (cell surface) 
Peptidoglycan (gram-positive bacteria); Lipoarabinomannan 
(mycobacteria); structural proteins (viruses); 
phospholipomannan (fungi); Glycosylphosphophatidyl inositol 
mucin (Trypanosoma) 
3 Endosome Single-stranded RNA and double-stranded RNA (viruses) 
4 Plasma membrane (cell surface) 
Lipopolysaccharides (gram-negative bacteria); Mannan 
glycoinositolphospholipids (Trypanosoma), structural proteins 
(viruses) 
5 Plasma membrane (cell surface) Flagellin (flagellated bacteria) 
6/2 * Plasma membrane (cell surface) 
Diacyl lipopeptides (Mycoplasma), LTA (Streptococcus), 
Zymosan (fungi); β-glucan (fungi) 
7 Endosome Single-stranded RNA (viruses) 
8 Endosome Single-stranded RNA (viruses) 
9 Endosome Double-stranded DNA viruses; unmethylated CpG motifs 
(bacteria and viruses); Hemozoin (Plasmodium) 
10 
Probably plasma membrane 
(cell surface) (199, 200) 
Unknown 
 
TLRs are type I transmembrane proteins that form homo- or heterodimers, as it is the 
case for TLR1, 2 and 6. They consist of an ectodomain that contains leucine-rich repeats and 
mediate the recognition of PAMPs, a transmembrane domain and cytosolic Toll-Interleukin 1 
(IL-1) receptor (TIR) domains that activate downstream signaling pathways by binding of 
distinct adaptor molecules for each TLR. TLR signaling finally leads to the activation of 
transcription factors such as NF-κB and interferon regulatory factors (IRFs) that induce 
expression of anti-microbial effector molecules like pro-inflammatory cytokines, chemokines 
and type I interferons such as IL-6, TNF-α and IFN-α/β (198). 
III.4.5 Toll-like receptors, EBV recognition and impact on EBV infection 
Herpesviruses are sensed by different TLRs and can interact with TLRs and TLR 
signaling, respectively, by blocking TLR signaling and corresponding immune responses, 
thus leading to immune evasion (201, 202). Until now, EBV itself has been shown to activate 
and modulate TLR2, 3, 7, and 9 signaling in various cell types (89, 202–207). However, there 
is evidence that TLR signaling can impact on EBV infection itself. Following EBV infection, 
it was demonstrated that activation of TLR9 via exogenous stimulation contributes to efficient 
transformation of B cells (208). Furthermore, activation of TLR9 and TLR7/8 signaling 
increased EBV-driven B cell proliferation and transformation (209, 210). Whereas TLR3 
stimulation in combination with an inhibiting drug against IAP (inhibitors of apoptosis) 
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elicited strong cytotoxic effects and inhibited proliferation of various EBV-positive and EBV-
negative NPC cell lines and xenografts (207). In addition, our group recently demonstrated 
that immune activation via TLR9 triggering could inhibit the switch from latent to lytic EBV 
upon de novo in vitro infection of cord blood B cells (211) and upon B cell receptor (BCR)-
induced reactivation of EBV in chronically infected BL cell lines (212). More recently, we 
demonstrated that in contrast to TLR9 activation, triggering of TLR2 with heat-killed group A 
streptococci (GAS) can induce lytic EBV reactivation in latently infected lymphoblastoid cell 
lines (LCLs), established from tonsillar mononuclear cells (TMCs) (213). Moreover, a very 
recent study shows that activation of TLR2, 3 and 4 in BL cell lines lead to up-regulation of 
lytic EBV genes (214). These results implicate that EBV could utilize TLR signalling 
potentially for I) driving latency, thus contributing to immune evasion and oncogenisis and 
for II) switching to lytic infection to ensure generation and amplification of progeny virus 
particle for transmission. Notwithstanding, these effects seem to be dependent on various 
factors, e.g. the physiological site of infection, the employed TLR and potentially the infected 
cell type. Although it is known that epithelial cells, including those of tonsils and upper 
airways, express TLRs and are capable of mounting innate immune responses (128, 191, 193, 
207, 215–222), the impact of TLR signaling on EBV infection in epithelial cells remains 
elusive. 	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IV SUBJECT OF INVESTIGATION 
EBV is a γ-herpesvirus with marked tropism for B cells. However, epithelial cells play 
an important role in the life cycle of EBV. Therefore, following aspects of the EBV infection 
in epithelial cells were subject of investigation within this thesis: 
1. What is the impact of hTERT expression and telomerase activity on EBV 
infection of epithelial cells? 
Increased telomerase activity is characteristic for epithelial stem and progenitor cells 
within the basal layers of epithelial tissues and a hallmark of cancer in general. Since EBV is 
transmitted via saliva, it has to overcome the epithelial barrier of the pharyngeal cavities, the 
portal of entry and exit for EBV, either to get access to the preferred B cell or to be spread to 
the next susceptible host. Additionally, EBV shows a tight association with epithelial cell 
malignancies such as nasopharyngeal and gastric carcinoma. However, EBV alone does not 
transform epithelial cells efficiently and is frequently lost from epithelial cells in vitro. We 
therefore investigated the impact and the contribution of hTERT expression and telomerase 
activity on the EBV infection in epithelial cells. 
2. What is the influence of hTERT expression and differentiation status on the 
susceptibility of epithelial cells to an infection by EBV? 
The infection by EBV relies mostly on attachment to the cellular receptor CD21 that is 
present on B cells but is only weakly or usually not at all expressed in epithelial cells. 
Additionally, integrins are well-known attachment receptors for various viruses and an 
involvement of certain integrins was demonstrated in the EBV infection of epithelial cells. 
Thus, we determined the integrin expression patterns in various epithelial cell lines and 
investigated whether increased hTERT expression or the differentiation status of primary 
epithelial cells from the sphenoidal sinus has an impact on expression of integrins that are 
involved in the infection of epithelial cells by EBV. 
3. What is the influence of TLR9 activation on EBV infection in epithelial cells? 
Various pathogens constantly challenge the pharyngeal cavity, the portal of entry for 
EBV. As part of the innate immune system, Toll-like receptors (TLRs) can sense specifically 
pathogen-associated molecular patterns and are therefore the first line of defense against 
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invading microorganisms. Epithelial cells within the pharyngeal cavity are known to express 
TLRs and to be capable of mounting innate immune responses. Recent studies of our group 
showed that activation of TLR9 can inhibit lytic reactivation in latently infected Burkitt’s 
lymphoma cells of EBV while TLR2 ligation in EBV-transformed lymphoblastoid cell lines 
can trigger lytic EBV replication. This prompted us to investigate the impact of TLR9 
activation on EBV infection in epithelial cells. 	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V RESULTS 
V.1 Manuscript I: Telomerase activity enhances Epstein-Barr virus gene expression 
and contributes to virus maintenance in epithelial cells 
Jürgen Rac, Florian Haas, Andrina Schumacher, Michele Bernasconi, Roberto F. 
Speck, David Nadal 
Manuscript in preparation 
V.1.1 Abstract 
Epstein-Barr virus (EBV) is a ubiquitous virus, tightly associated with various 
lymphoid and epithelial malignancies. Epithelial stem cells and transiently proliferating cells 
within the basal layers of epithelial tissues exhibit unlimited self-renewal capacity mediated 
by activated telomerase activity. During cell division, these cells might acquire genetic and 
epigenetic alterations generating an environment to support persistent EBV infection. 
Amongst these alterations, loss of p16 and overexpression of cyclin D1 appear to be crucial 
for the establishment of an EBV infection in epithelial cells and are known to be common 
features in EBV associated epithelial tumors. However, the impact of telomerase activity on 
the infection of epithelial cells remains to be elucidated. Therefore, we generated epithelial 
model cell lines with increased telomerase activity by stable ectopic expression of hTERT, the 
rate-limiting component of the telomerase complex. Conversely, we suppressed telomerase 
activity by stable expression of a catalytically inactive, dominant negative hTERT mutant. We 
then performed infection experiments using a recombinant wild type EBV strain encoding 
GFP and determined infection rates by flow cytometry as well as EBV gene expression by 
RT-qPCR. We found that the infection is strongly depending on the cellular context and that 
infection frequencies partly depend on telomerase activity. Moreover, epithelial cells with 
increased telomerase activity showed up-regulation mainly of latent EBV genes as compared 
to their corresponding control cell lines. We conclude that increased telomerase activity 
directly acts on the EBV infection of epithelial cells by facilitating latent EBV gene 
expression and therefore contributing to EBV maintenance in epithelial cells. 
For detailed information see attached Manuscript I. 
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V.1.2 Complementary Data and Results to Manuscript I 
Integrin expression patterns in various epithelial cell lines 
Epithelial cells commonly lack or show only low expression of CD21 (146), the main 
receptor for EBV attachment. Adhesion molecules such as integrins are well known 
attachment receptors for various viruses (151, 152). Several studies showed involvement of 
αV, α3, α5, β1, β6 and β8 integrins in the infection of epithelial cells by EBV (153–155, 159). 
The RGD motif of the viral transmembrane envelope glycoprotein BMRF2 was shown to 
bind to integrin αV, α3, α5 and β1 of oral epithelial cells (153, 155) and the integrins αVβ6 
and αVβ8 appear to trigger membrane fusion via the KGD motif of the transmembrane 
envelope glycoprotein complex gH/gL of EBV (159). To identify and characterize potential 
candidates for further studies, we determined the expression of these integrins in various 
epithelial cell lines as shown in Figure 4. With the exception of integrin β6 all tested integrins 
showed robust expression at mRNA level in all cell lines. The expression of β6 was weak in 
HEK293 (Figure 4C) and not detectable in Ad-AH cells (Figure 4E). All cell lines were 
subjected to direct infection by spinoculation with a recombinant wild type EBV strain 
encoding for GFP. We achieved the highest infection frequencies in AGS and HEK293 cells 
(see attached manuscript I; Figure 3) while the remaining cell lines were not or only weakly 
susceptible to infection by EBV (data not shown). Therefore, we chose these cell lines and 
additionally HONE-1 cells, as nasopharyngeal carcinoma model for our study as described in 
the attached manuscript I. 	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Since hTERT-overexpressing cells showed at least in part increased infection 
frequencies as compared to the corresponding control cells (see attached manuscript I; Figure 
3), we asked whether the expression of hTERT can regulate the expression of integrins, which 
are known to be involved in EBV attachment and entry in epithelial cells. We hypothesized 
that increased hTERT expression might up-regulate the expression of integrins and therefore 
lead to increased susceptibility to infection by EBV. We compared the integrin expression 
Figure 4: Integrin gene expression patterns in various epithelial cell lines. Integrin gene expression was 
determined in HONE-1 (A), AGS (B), HEK293 (C), Detroit562 (D), Ad-AH (E) and HeLa (F) cells by RT-
qPCR relative to HMBS. Data is represented as Mean from 3 technical replicates of one experiment; n.d. = not 
detected. 
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pattern as described before, in wild type and hTERT-overexpressing HEK293 cells. As shown 
in Figure 5 we did not detect any significant difference that would lead to increased infection 
susceptibility. Unexpectedly, we found a loss of integrin β6 expression in HEK293-hTERT 
cells. We conclude that hTERT is not involved in the regulation of integrin expression and 
that the differences seen in the infection frequencies might be not ascribed to increased 
susceptibility to infection by EBV. 	  
 
 
 
 
 
 
 
 
Integrin expression patterns in primary sphenoidal epithelial cells 
The susceptibility to infection by EBV was demonstrated by Feederle et al. to be 
dependent on the differentiation status of epithelial cells (164). Thereby, differentiated or late 
passage sphenoidal epithelial cells (sECs) showed a higher susceptibility to direct infection by 
EBV than less differentiated or early passage sECs. Since hTERT expression and telomerase 
activity is attributed to stem and progenitor cells within the basal layer of the epithelium we 
hypothesized that differentiated epithelial cells without hTERT expression and telomerase 
activity might show increased expression of integrins that contribute to infection of epithelial 
cells by EBV. To investigate the expression of the integrins, mentioned above, we received 
frozen cell pellets of sECs in early (passage number 2) and late (passage number 6-7) 
passages as a kind gift from Regina Feederle (German Cancer Research Center, Heidelberg, 
Germany). We isolated the total RNA, prepared cDNA and determined the gene expression 
levels by RT-qPCR relative to the housekeeping gene HMBS. We found no obvious 
Figure 5: Integrin gene expression pattern in wild type and hTERT 
overexpressing HEK293 cells. Integrin gene expression was determined in 
wild type (HEK293-WT; white columns) and in hTERT overexpressing 
(HEK293-hT; black columns) HEK293 cells by RT-qPCR relative to 
HMBS. Data is represented as Mean ± SD from 3 independent experiments; 
n.d. = not detected. 
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difference between early and late passage sECs regarding their integrin gene expression levels 
as shown in Figure 6. Nevertheless, late passage sECs showed slightly increased expression 
levels of all integrins tested except of β8. These results indicate that late passage epithelial 
cells might be more susceptible to EBV due to increased expression of integrins, known to be 
involved in the infection of epithelial cells. However, this appears to be in contrast with the 
well-known fact that integrin expression is found predominantly in the basal layers of 
multilayered epithelia. Differentiation and migration of epithelial cells to the apical surface of 
the epithelium is accompanied by a relative loss of integrin expression (223, 224). 
Additionally, we investigated the hTERT gene expression within early and late passage sECs. 
In total, we could detect hTERT gene expression only in 4 out of 9 samples at very low levels 
(relative gene expression <10-2; data not shown). Whereas 1 early passage sEC (passage 
number 2), 2 intermediate passage sECs (passage number 4-5) and 1 of the late passage sECs 
(passage number 7) were positive for hTERT. These results additionally indicate that the 
susceptibility to infection by EBV is not dependent on hTERT expression. 
 
 
 
 
 
 
 
Growth properties of wild type and hTERT-overexpressing epithelial cell lines 
Higher infection frequencies in hTERT-overexpressing cells as compared to control 
cells (see attached manuscript I; Figure 3) might be due to faster proliferation of cells with 
increased hTERT levels. Therefore, we investigated the proliferation characteristics of 
hTERT-overexpressing cells in comparison to the corresponding wild type cell lines by 
Trypan Blue exclusion and MTS assay as shown in Figure 7. Using the Trypan Blue 
exclusion assay, we did not observe any significant difference between wild type and hTERT-
Figure 6: Integrin gene expression pattern in early and late passage 
sECs. Integrin gene expression was determined in early (white columns) and 
late (black columns) passage sECs by RT-qPCR relative to HMBS. Data is 
represented as Mean ± SD from 3 individual donors. 
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overexpressing cells. Interestingly, we found slightly reduced proliferation rates in HONE-1-
hTERT (Figure 7A) and AGS-hTERT (Figure 7B) cells in comparison to their corresponding 
wild type cells while the proliferation of HEK293-hTERT was similar to wild type HEK293 
cells (Figure 7C). However, when we determined the proliferation capacity by MTS assay, 
HONE-1-hTERT cells showed comparable results to wild type HONE-1 cells (Figure 7D) 
whereas wild type AGS and AGS-hTERT cells (Figure 7E) showed similar results as 
compared to the corresponding Trypan Blue exclusion assay in Figure 7B. HEK293-hTERT 
cells showed significantly increased proliferation rates in comparison to wild type HEK293 
cells when we used the MTS assay (Figure 7F). However, with the MTS assay one does not 
necessarily detect directly cell proliferation. The MTS assay is used to detect metabolic 
activity that is usually correlating with cell proliferation since proliferating cells are highly 
metabolically active. Since AGS-hTERT cells showed lower proliferation rates with both 
assays and HEK293-hTERT cells showed only higher proliferation rates using the MTS 
assay, we conclude that hTERT-overexpression does not substantially impact on the 
proliferation, which is in line with the findings of Hahn et al. (225), showing that increased 
expression of hTERT does not lead to enhanced proliferation in various cancer cell lines. 
Taken together, these results indicate that the proliferation capacity of hTERT-overexpressing 
cells does not account for the increased infection frequencies. 
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Figure 7: Proliferation characteristics of wild type and hTERT-overexpressing epithelial cell lines. 
Proliferation of wild type (white columns) and hTERT-overexpressing epithelial cell lines was determined by 
Trypan Blue exclusion assay (A-C) and by MTS assay (D-F) in HONE-1 vs. HONE-1-hTERT (A, D), AGS vs. 
AGS-hTERT (B, E) and HEK293 vs. HEK293-hTERT (C, F) cells. Data was normalized to the starting time 
point 24h and is represented as Mean ± SD of 3 independent experiments. * = p<0.05 (unpaired t test; Holm-
Sidak method). 
A 
D 
C B 
E F 
RESULTS 	  
 
34 
V.2 Manuscript II: TLR9 stimulation in epithelial cells does not drive Epstein-Barr 
virus into latency 
Jürgen Rac, Florian Haas, Michele Bernasconi, Roberto F. Speck, David Nadal 
Manuscript in preparation 
V.2.1 Abstract 
The ubiquitous γ-herpesvirus EBV is very successful in infecting >90% of the human 
population. EBV is transmitted via saliva to the next susceptible host and thus the pharyngeal 
cavities are portal of entry and exit for Epstein-Barr virus (EBV). Various microbes with 
specific pathogen associated molecular patterns (PAMPs) constantly challenge the oral 
mucosal epithelial tissues lining the pharyngeal cavities. As a first line of defense, the innate 
immune system recognizes these microorganisms via pattern recognition receptors (PRRs) 
such as Toll-like receptors (TLRs). Signaling triggered by TLR stimulation results in 
expression of pro-inflammatory cytokines, chemokines and anti-microbial effector molecules 
and is therefore contributing to shape the adaptive immunity as a second response to invading 
pathogens. Apart from the mechanical and physical barrier function of pharyngeal epithelial 
cells, they express TLRs and are capable of mounting an innate immune response. Thus 
epithelial cells of the pharyngeal cavity play a pivotal role not only within the life cycle of 
EBV. Recently we have demonstrated that TLR9 activation can suppress the reactivation 
from latent to lytic EBV infection in EBV positive Burkitt’s lymphoma cells whereas 
triggering of TLR2 in latently infected lymphoblastoid cell lines elicits lytic EBV replication. 
However, the impact of activated TLR signaling on the infection of epithelial cells by EBV 
remains elusive. Therefore, we investigated the effect of TLR9 stimulation on EBV infection 
of epithelial cells. Here, we show that TLR9 triggering with synthetic ligands has no impact 
on EBV infection of the stably TLR9-expressing epithelial model cell line HEK293 and its 
wild type counterpart. Additionally, our results indicate that both cell lines might actually not 
be suitable as epithelial cell models to study the effect of TLR signaling on the infection of 
epithelial cells by EBV, but they suggest a contributing role of TLR activation in epithelial 
cells to EBV reactivation from latency. 
For detailed information see attached Manuscript II. 
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V.2.2 Complementary Data and Results to Manuscript II 
TLR expression patterns in various epithelial cell lines 
TLRs play a central role in the innate immune defense mechanisms against invading 
pathogens, as already mentioned in the attached manuscript II. Since EBV is an orally 
transmitted virus, it first encounters the epithelial cells within the pharyngeal cavity before 
EBV gets access to its preferred target, the B cells. Epithelial cells within the pharyngeal and 
sinonasal cavities are known to express TLRs, whereas mainly TLR2, 3 and 4 seem to be 
important in primary epithelial cells and cell lines from the pharynx. Nevertheless, we 
recently demonstrated that TLR9 triggering can inhibit lytic EBV replication upon primary 
infection of B cells and suppresses the switch from latent tor lytic EBV in latently infected BL 
cells in vitro (211, 212). By contrast, TLR2 activation using heat-killed GAS elicited lytic 
EBV replication in latently infected LCLs established from TMCs (213). This goes along with 
the finding that GAS colonized patients shed substantially higher numbers of EBV particles 
into saliva (213). However, the impact of TLR activation on the infection of epithelial cells by 
EBV remains elusive and we decided to investigate the role of TLR9 activation on EBV 
infection of epithelial cells. Therefore, we screened several epithelial cell lines for their TLR 
gene expression patterns as shown in Figure 8. It turned out that the TLR gene expression 
pattern is quite heterogeneous amongst the tested cell lines. While we detected expression of 
TLR1, 3 and 6 in all cell lines, including HEK293 (see attached manuscript II; Figure 1), the 
expression of the remaining TLRs was inconsistent. However, the nasopharyngeal carcinoma 
cell line Detroit562 (Figure 8C) was the only cell line that expressed all TLR, characteristic 
for pharyngeal epithelial cells. Since HEK293 was the only cell line with detectably levels of 
TLR9, apart from HONE-1 and AGS, and had the highest susceptibility direct infection by 
EBV we chose the cell line HEK293 for our study as described in the attached manuscript II. 
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Figure 8: TLR gene expression patterns in various epithelial cell lines TLR gene expression was determined 
in HONE-1 (A), AGS (B), Detroit562 (C), Ad-AH (D) and HeLa (E) cells by RT-qPCR relative to HMBS. Data 
is represented as Mean from 3 technical replicates of one experiment; n.d. = not detected. 
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TLR expression patterns in primary sphenoidal epithelial cells 
In addition to the investigation of the TLR gene expression patterns in the epithelial 
model cell lines, we determined the TLR gene expression in the primary sECs (Figure 9). In 
general, these cells showed almost the same expression pattern like the nasopharyngeal cell 
line Detroit562 (Figure 8C). The only difference was the lack of TLR7 expression, which was 
present in Detroit562 cells, and the expression of TLR9, which was absent in Detroit562 cells. 
Since we did not observe any significant effect of TLR9 activation on EBV infection of wild 
type and TLR9-expressing HEK293 cells, these results suggest that primary epithelial cells 
such as sECs and tonsillar epithelial cells, might be more suitable models to test the impact of 
TLR activation on the infection of epithelial cells. Contributing to this finding we compared 
as well the TLR expression in early and late passage sECs. Since late passage sECs reflect 
more differentiated cells, potentially located at the apical epithelial surface and therefore more 
frequently exposed to invading microorganisms, we hypothesized that these cells might 
express higher TLR levels compared to early passage or less differentiated sECs. This would 
render them potentially more sensitive to pathogens and evoke a stronger innate immune 
response. Although we did not detect any significant difference between early and late 
passage sECs, we observed at least a slightly increased expression of TLR1, 2, 3, 4 and 5 in 
late passage sECs (Figure 9). Taken together, these results indicate that primary sECs and 
especially differentiated cells might provide a suitable model to study the impact of TLR 
activation on the infection of epithelial cells by EBV. 
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Figure 9: TLR gene expression patterns in early and late passage sECs. 
TLR gene expression was determined in early (white columns) and late 
(black columns) passage sECs by RT-qPCR relative to HMBS. Data is 
represented as Mean ± SD from 3 individual donors; n.d. = not detected. 
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VI COMPLEMENTARY MATERIAL AND METHODS 
For detailed descriptions of materials and methods that are not mentioned within this 
section, please refer to the attached manuscripts I & II. 
Cells 
As additional model epithelial cell lines we used the nasopharyngeal carcinoma (NPC) 
cell line Detroit562 (226, 227), maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM; Sigma-Aldrich, Buchs, Switzerland), the cervical adenocarcinoma cell line HeLa 
(228), maintained in RPMI-1640 (Sigma-Aldrich), and the nasopharyngeal cell line Ad-AH 
(229), kindly provided by Claire Shannon-Lowe (University of Birmingham, Birmingham, 
United Kingdom), as well maintained in RPMI-1640. All media were supplemented with 10% 
heat inactivated Fetal Bovine Serum (FBS; Sigma-Aldrich), 1% L-Glutamine and 1% 
Penicillin/Streptomycin (Gibco, Zug, Switzerland). Frozen cell pellets sphenoidal sinus 
epithelial cells (sECs) were kind gifts from Regina Feederle and Henri-Jacques Delecluse 
(German Cancer Research Center, Heidelberg, Germany) (164). 
Gene expression analysis by RT-qPCR 
Integrin gene expression was determined using a pre-validated primer/probe assays for 
integrin αV (Hs00233808), α5 (Hs01547673), α3 (Hs00233722), β1 (Hs00559595), β3 
(Hs01001469), β5 (Hs00174435), β6 (Hs00168458) and β8 (Hs01110394) (all from Applied 
Biosystems; Zug, Switzerland). For detailed description of RNA isolation, cDNA preparation, 
RT-qPCR reactions, calculation and analysis of the data please refer to the attached 
manuscripts I & II. 
Cell proliferation analysis 
Proliferation of wild type and hTERT-overexpressing epithelial cells was determined 
by Trypan Blue exclusion and a colorimetric (MTS) assay. Briefly, for the Trypan Blue 
exclusion assay, 5x104 cells/well were seeded in 24-well plates (TPP, Trasadingen, 
Switzerland) and incubated at 37°C with 5% CO2. At 24 h, 48 h and 72 h post seeding cells 
were detached, using 0.25% Trypsin-EDTA (Gibco, Zug, Switzerland), washed with 1x 
phosphate buffered saline (PBS; Gibco, Zug, Switzerland), resuspended in 1 ml 1x PBS and 
10 µl cell suspension were mixed with 10 µl 0.4% Trypan Blue dye (Gibco). The mix was 
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transferred to a hemocytometer and unstained (live) cells were counted. The total number of 
live cells was calculated on the basis of the cell suspension volume (1 ml 1x PBS) and the 
dilution factor (1:2) of the mix. Calculated total number of live cells was normalized to the 
starting time point at 24h post seeding. All cell lines were counted at least in duplicate for 
each experiment. 
For the MTS assay, the CellTiter 96® AQueous One Solution Cell Proliferation Assay 
(Promega, Dübendorf, Switzerland) was used according to manufacturer’s instructions. 
Briefly, 5x103 cells/well were seeded on 96-well flat bottom plates (Sarstedt, Sevelen, 
Switzerland) and incubated at 37°C with 5% CO2. At 24 h, 48 h and 72 h post seeding, 
20 µl/well CellTiter 96® AQueous One Solution Reagent (containing the tetrazolium compound 
MTS) were added, incubated for 2 h at 37°C and the absorbance at 490 nm was determined 
using the Synergy HT plate reader (BioTek, Luzern, Switzerland). Medium alone served as 
blank control to determined the background absorbance that was subtracted from the signal 
obtained for each sample. The absorbance was normalized to the starting time point at 24 h 
post seeding. All reactions were carried out in triplicates for each experiment. 
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VII GENERAL DISCUSSION AND OUTLOOK 
The B-lymphotropic γ-herpesvirus EBV is transmitted via saliva to the next naïve 
host. Thus, the portal of entry and exit for EBV are the pharyngeal cavities that are in addition 
constantly challenged by various microbes. The mucosal epithelia lining the oro- and 
nasopharynx are therefore the first and the last barrier EBV has to overcome to get access to 
its preferred target cell, the B cell. Thus, epithelial cells play a pivotal role within the life 
cycle of EBV and it is not surprising that EBV is as well associated with epithelial cell 
malignancies like NPC and GC. Within this work I performed studies on two different aspects 
of the EBV infection in epithelial cells. First, we investigated the contribution of hTERT, the 
rate-limiting component of the telomerase, on EBV infection in epithelial cells (see attached 
manuscript I). Second, we studied the impact of TLR9 activation on the infection of epithelial 
cells by EBV (see attached manuscript II). The obtained results will be discussed within this 
section with regard to the putative role of the epithelium as transit route for EBV during its 
the life cycle. 
EBV infection in vivo 
While the infection of B cells by EBV has been studied extensively and is quite well 
understood, the infection biology and the role of epithelial cells within the life cycle of EBV 
still remains puzzling and mostly elusive. This is partly due to the lack of suitable in vitro 
epithelial cell infection models for EBV. Soon after the isolation of EBV, it has been 
demonstrated that EBV is shed within the pharyngeal cavities into saliva and oropharyngeal 
epithelial cells were considered to be the potential source of the progeny virus for 
transmission (230–234). In vivo, EBV is only found in a latent state in EBV-associated 
epithelial malignancies such as NPC and EBVaGC as discussed in the introduction. Lytic 
EBV replication was found to occur in the context of oral hairy leukoplakia (OHL), an 
acquired immunodeficiency syndrome (AIDS)-associated epithelial lesion at the lateral 
margin of the tongue (235–239) and further evidence suggests that reactivation of lytic EBV 
infection most commonly occurs in tonsillar plasma cells as well as in tonsillar B-cells (184, 
240–242). In addition, it has been difficult or even impossible to find any evidence of lytically 
infected epithelial cells in immunocompetent individuals (181, 182). Reactivation and lytic 
replication of EBV in B cells alone cannot account for the large amounts of virus found in 
saliva (100). This finding is further supported by the observation of oropharyngeal EBV 
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shedding in the absence of circulating B cells in patients treated with the anticancer drug 
rituximab (243). However, the treatment with rituximab does not entirely eliminate 
lymphocytes from lymphoid tissues (244, 245), as these are present in NALT. Taken together, 
the cellular source of progeny virus for transmission is a matter of debate and still needs to be 
identified. Speculatively, it might be a cooperation of both, reactivation of EBV in B 
lymphocytes and lytic EBV infection of epithelial cells, e.g. within the lymhoepitelium of the 
NALT where B cells and epithelial cells are in close proximity to each other. In support of 
this theory comes the observation that EBV can lytically replicate in tonsillar plasma cells 
(184). In conclusion, these findings imply more a role as transit route or the epithelium within 
the life cycle of EBV as already suggested by others (160, 240). 
EBV infection in vitro 
The failure to detect EBV-infected epithelial cells in vivo, apart from latently infected 
tumor cells and the tongue lesion in OHL, is clearly reflected in vitro. The in vitro infection of 
epithelial using cell-free EBV is difficult to achieve and not efficient (162). However, several 
infection mechanisms have been proposed and demonstrated, as mentioned in the 
introduction. One major breakthrough in the understanding of the infection biology of EBV in 
epithelial cells was considered the investigation of cell-to-cell contact infection, using either 
EBV-infected B cells or EBV-loaded B cells as transfer vehicle (25). However, the findings 
are controversial. While Tugizov et al. reported efficient infection of polarized 
nasopharyngeal epithelial cells using infected lymphoblastoid cell lines from the apical 
surface (153), Shannon-Lowe et al. reported efficient and rapid transfer infection using EBV-
loaded primary B cells from the basolateral surface of primary tonsillar epithelial cells (167). 
This suggests differences between cell-to-cell contact and B cell-mediated transfer infections. 
However, both approaches generate EBV particles more specific for epithelial cells, as 
predicted by the concept of switch in EBV cell tropism (143). However, epithelial cells in the 
upper apical epithelial layers lack expression of integrins that potentially serve as EBV 
receptors. Speculatively, this suggests that cell-to-cell contact-mediated infection of epithelial 
cells from the apical surface occurs via membrane fusion without release of EBV from B 
cells. By contrast, reactivation of EBV in B cells, release of EBV and subsequent binding of 
EBV to B cells would be needed for B cell-mediated transfer infection of epithelial cells from 
the basal surface. Following the hypothesis, attachment of EBV to the B cells would lead to 
conformational changes within the viral envelope, thus giving rise to the viral ligands for the 
epithelial receptors, e.g. integrins, at the basal surface of epithelial cells as mentioned in the 
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introduction. On the other hand, fusion of B cells and epithelial cells might potentially occur 
in vivo from the basal surface as well. Membrane fusion was demonstrated in in vitro assays 
via the viral glycoprotein complex gHgL and the cellular integrins αVβ5, αVβ6 and αVβ8 
(157–159). B cell-mediated transfer infections from the basal epithelial surface might be 
biologically more relevant in the in vivo situation since the presence of B cells in saliva is 
probably very rare. Notwithstanding, the exact mechanisms of cell-to-cell contact and B cell-
mediated transfer infections remain to be elucidated. Nevertheless, EBV might employ both 
mechanisms in vivo in addition to cell-free infection mechanisms at different steps during its 
life cycle. The infection of epithelial cells with cell-free EBV in general is difficult to achieve 
in vitro, as mentioned above. Nevertheless, infection of polarized nasopharyngeal epithelial 
cells was reported to be more efficient from the basolateral surface (153, 155). Additionally, 
EBV was demonstrated to be bi-directionally transcytosed through polarized primary tonsillar 
epithelial cells (160). Moreover, basal to apical transcytosis might be facilitated in vivo 
through EBV-specific IgA molecules (147, 148), whereas gp350/220-specific IgG molecules 
in saliva might facilitate EBV entry into the epithelium from the apical surface (143, 166). 
The finding that EBV in the saliva contains higher levels of gp42 (246) indicates that EBV 
was produced in epithelial cells and further contributes to the hypothesis that EBV might 
directly infect B cells residing in the epithelium. Thus supporting the possibility that 
transmitted EBV could initially bypass the epithelium, without productive infection of 
epithelial cells, either by transcytosis or within infected B cells before reaching the host B cell 
pool and persisting life-long. 
The epithelium and its potential role as transit route for EBV 
Taken together, the role for the epithelium within the life cycle of EBV is ambiguous. 
It seems that most of the strategies used by EBV to overcome the epithelial barrier are more 
or less of unspecific nature. That’s probably because we still do not completely understand 
them. Nonetheless, EBV is able to infect epithelial cells via various mechanisms or can be 
transported through the epithelium without a productive infection of epithelial cells. 
Therefore, I agree with the proposed role as transit route for the epithelium in the life cycle of 
EBV. Moreover, from my point of view, the infection of susceptible epithelial cells by EBV 
within the basal epithelial layers occurs rather accidently, while the interplay between B cells 
and epithelial cells in the upper epithelial layers (more differentiated) might be necessary for 
virus amplification. The known mechanisms how EBV may overcome the epithelia within its 
putative portal of entry and exit, the pharyngeal cavities, are summarized in Figure 10. 
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Telomerase and its impact on the EBV infection in epithelial cells 
Telomerase expression and activity is usually restricted to continuously proliferating 
cells such as stem cells and it is as well a hallmark of cancer (125, 126). Epithelial stem cells 
with self-renewal capacity and indefinite proliferation capability are located within the basal 
layers of epithelial tissues (127–132). Since EBV has to bypass the epithelium, either to get 
access to the B cells or to be released and transmitted, it is likely that EBV comes into contact 
Figure 10: Model for epithelium as transit station within the life cycle of EBV. Mainly EBV with increased 
B cell tropism (B-EBV, red) is transmitted via saliva as cell-free virions (I.a/c), or within infected B cells that 
directly lytically infect differentiated epithelial cells by cell-to-cell contact (I.b). Cell-free B-EBV might directly 
attach and enter B cells that reside within the epithelium (I.c), e.g. in the lymphoepithelia of the nasopharynx-
associated lymphoid tissue (NALT). B-EBV is then transcytosed through the epithelial layers either as cell-free 
virus (II.a). Whereas EBV establishes a latent infection upon entry into the epithelia-associated B cells, which 
then translocate/transmigrate through the epithelium (II.b). Transcytosed B-EBV then infects B cells located in 
the lamina propria and submucosa (III.a). EBV-infected B cells (III.a/b) subsequently enter the B cell-associated 
part of the EBV life cycle (IV.), where EBV persists life-long in a latent state within the host B cell pool. 
Latently infected B cells might leave the B cell pool again (V.a) or lytically reactivate where progeny EBV with 
increased epithelial tropism (E-EBV, blue) is produced (V.b). Latently infected B cells might as well again 
translocate/transmigrate through the epithelium (VI.a). In addition, EBV might reactivate in latently infected B 
cells within the epithelium, which then transfer E-EBV to differentiated epithelial cells in the upper layers of the 
epithelium where lytic EBV replication takes place (VI.b). Together, this leads to EBV amplification and 
production mainly of B-EBV for transmission. Additionally, cell-free E-EBV might be transcytosed through the 
epithelium, which could be facilitated by EBV-specific IgA molecules (VI.c). Finally, latently infected B cells 
and cell-free EBV are released into saliva and transmitted to the next susceptible host (VII.). Apart from EBV 
transmission, susceptible epithelial cells within the basal epithelial layer might be infected by cell-free E-EBV or 
by B cell-mediated E-EBV transfer (VIII.), which might lead to latent infection and clonal outgrowth of 
epithelial cells, thus ultimately to the development of tumors (IX.) such as NPC. 
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with these epithelial stem cells. Due to EBV’s tight association with epithelial malignancies 
such as NPC and EBVaGC we investigated the impact of hTERT on the EBV infection in 
epithelial cells (see manuscript I). Therefore we generated epithelial model cell lines with 
either increased hTERT expression levels or overexpression of a catalytically inactive 
dominant negative mutant DNhTERT. We found that increased telomerase expression and 
activity led to increased infection frequencies in the EBV susceptible, hTERT-overexpressing 
(hT) cell lines AGS-hT and HEK293-hT. In contrast, suppression of telomerase activity by 
ectopic expression of DNhTERT (DN) resulted in reduced infection frequencies at least in 
AGS-DN cells. Additionally, we showed that the EBV infection of epithelial cells is strongly 
dependent on the cellular context. Interestingly, increased hTERT expression and telomerase 
activity led to up-regulation mainly of latency-associated EBV genes. We therefore concluded 
that increased telomerase expression and activity contributes to EBV maintenance and in turn 
might facilitate tumor development and progression. It remains unclear whether cells with 
increased hTERT expression are more susceptible to an infection by EBV or if cells with 
reduced telomerase activity are not able to maintain the virus and therefore show lower 
infection frequencies. Nevertheless, our results are complementary to the observation that 
telomerase-immortalized primary nasopharyngeal cell clones could support a long-term EBV 
infection in vitro (60, 185). However, we did not find induction of lytic EBV replication due 
to suppression of telomerase expression and activity as demonstrated in B cells (187, 188). In 
general, the results of this study contribute to the hypothesis that EBV infection is a late or 
secondary event within the development of NPC and EBVaGC since latent and persistent 
EBV infection in epithelial cells is obviously dependent on cellular alteration such as loss of 
p16 activity and cyclin D1 overexpression (25). Such cellular alterations might be acquired by 
epithelial stem cells due to their self-renewal capacity and their proliferation capability. 
Moreover, EBV might activate telomerase activity via LMP1 since it was demonstrated that 
LMP1 can activate the hTERT promoter in B cells and epithelial cells (82, 124). Interestingly, 
LMP1 showed the strongest up-regulation in our hTERT-overexpressing model cell lines, 
indicating that telomerase activity and LMP1 expression might cooperate within a positive 
feedback loop. Taken together, our results support the role of EBV as a late event in NPC and 
EBVaGC and the latent EBV infection in combination with increased telomerase activity 
might facilitate tumor development and might be responsible for rapid tumor progression. 
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TLR activation and its impact on the infection of epithelial cells by EBV 
Our second study focused on the influence of the innate immune mechanisms on the 
EBV infection in epithelial cells. Since various microbes constantly challenge the pharyngeal 
cavities, as portal of entry and exit for EBV, we hypothesized that an activated innate immune 
system might have an influence on the EBV infection in epithelial cells. More precisely, we 
tested the impact of TLR9 stimulation (see manuscript II). As part of the innate immune 
system, TLRs play a pivotal role within the first line of defense against invading pathogens. 
Activated TLR signaling ultimately leads to the expression of anti-microbial effector 
molecules such as pro-inflammatory cytokines, chemokines and type I interferons (198) and 
thus TLRs are crucial for preventing infections of the host. Upon TLR stimulation different 
scenarios can be imagined. First, TLR activation in epithelial cells might either block or 
facilitate EBV infection of epithelial cells. Second, activated TLR signaling by chronic 
stimulation might facilitate a latent EBV infection, leading expansion and malignant 
outgrowth of infected cells. Third, stimulation of TLRs in epithelial cells might serve as alarm 
signal and trigger lytic EBV replication and amplification, thus facilitating EBV transmission. 
However, in our in vitro model system we did not observe any significant effect of activated 
TLR9 signaling on the infection of the used epithelial model cells. Activation of TLR9 with 
two different synthetic TLR9 ligands had no impact on the infection frequencies of the tested 
epithelial model cell lines. Additionally, EBV gene expression did not show any significant 
changes due to TLR9 activation. It is possible that the employed epithelial model cell lines do 
not reflect the physiological in vivo situation to study the impact of TLR activation on the 
EBV infection in epithelial cells. Nevertheless, our group has recently shown that TLR9 
triggering can inhibit the switch from latent to lytic EBV upon de novo in vitro infection of 
cord blood B cells (211) and upon B cell receptor (BCR)-induced reactivation of EBV in 
chronically infected BL cell lines (212). In addition we demonstrated that TLR2 ligation 
could induce lytic EBV reactivation in latently infected LCLs (213), whereas others have 
shown that activation of TLR2, 3 and 4 in BL cell lines led to up-regulation of lytic EBV 
genes (214). Taken together, these studies show that TLR signaling has an impact on EBV 
infection in general or at least in B cells. Nevertheless, these effects seem to be dependent on 
various factors, e.g. the physiological site of infection, the expressed TLR and potentially the 
infected cell type. 
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Future perspectives 
In summary, the main findings of the work presented here show that EBV might 
benefit from the infection of epithelial cells with increased telomerase expression and activity, 
while the impact of activated TLR signalling on the EBV infection in epithelial cells remains 
elusive. Further efforts should focus on the establishment and the study of primary epithelial 
cell cultures. especially on polarized epithelial cell, epithelial stem cell and tissue cultures and 
the mechanisms how EBV might overcome theses barriers with regard to transcytosis of EBV 
as for example demonstrated by Tugizov et al. (160). Additionally, variations amongs EBV 
strains should be considered for further studies on the infection biology of EBV in epithelial 
cells since there are obviously EBV strains with markedly increased epithelial tropism as 
shown by Tsai et al. (165). Such studies might facilitate the understanding of EBV and its 
relation to epithelial cells and associated malignancies. 	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IX.1.1 Abstract 
Epstein-Barr virus (EBV) is a ubiquitous virus, tightly associated with various 
lymphoid and epithelial malignancies. Epithelial stem cells and transiently proliferating cells 
within the basal layers of epithelial tissues exhibit unlimited self-renewal capacity mediated 
by activated telomerase activity. During cell division, these cells might acquire genetic and 
epigenetic alterations generating an environment to support persistent EBV infection. 
Amongst these alterations, loss of p16 and overexpression of cyclin D1 appear to be crucial 
for the establishment of an EBV infection in epithelial cells and are known to be common 
features in EBV associated epithelial tumors. However, the impact of telomerase activity on 
the infection of epithelial cells remains to be elucidated. Therefore, we generated epithelial 
model cell lines with increased telomerase activity by stable ectopic expression of hTERT, the 
rate-limiting component of the telomerase complex. Conversely, we suppressed telomerase 
activity by stable expression of a catalytically inactive, dominant negative hTERT mutant. We 
then performed infection experiments using a recombinant wild type EBV strain encoding 
GFP and determined infection rates by flow cytometry as well as EBV gene expression by 
RT-qPCR. We found that the infection is strongly depending on the cellular context and that 
infection frequencies partly depend on telomerase activity. Moreover, epithelial cells with 
increased telomerase activity showed up-regulation mainly of latent EBV genes as compared 
to their corresponding control cell lines. We conclude that increased telomerase activity 
directly acts on the EBV infection of epithelial cells by facilitating latent EBV gene 
expression and therefore contributing to EBV maintenance in epithelial cells. 
IX.1.2 Introduction 
The Epstein-Barr virus (EBV), a member of the γ-herpesvirus family, is very 
successful in infecting over 90% of the adult human population (Rickinson & Kieff, 2007). 
Primary infection with EBV is usually asymptomatic or causes unspecific symptoms. In 
individuals older than 5 years of age, however, primary infection may manifest as infectious 
mononucleosis. Importantly, EBV has been linked to various lymphoid and epithelial cell 
malignancies, e.g. Burkitt’s lymphoma (BL), Hodgkin’s lymphoma, gastric carcinoma (GC) 
and nasopharyngeal carcinoma (NPC) (Kieff & Rickinson, 2007). Upon infection of its main 
target cells, the B-cells, where EBV eventually persists, the virus enters its default mode of 
infection called latency (Rickinson & Kieff, 2007). This goes along with restricted viral gene 
expression and therefore a maximum level of immune evasion (Griffin et al., 2010; Hislop et 
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al., 2007; Rickinson & Kieff, 2007; Speck & Ganem, 2010; Taylor & Blackbourn, 2011). By 
contrast, the lytic replication mode or so called productive infection results in production of 
infectious progeny virus (Kieff & Rickinson, 2007). 
As an orally transmitted microbe, EBV has to overcome the oral mucosal epithelium 
to be shed into saliva and spread to susceptible hosts. Thus, the oral mucosal epithelium plays 
a crucial role in EBV life cycle. Since EBV was the first human oncogenic virus discovered 
(Epstein et al., 1964) it is not surprising that there are tight associations with epithelial cell 
carcinomas apart from B-cell derived tumors like BL. It is suggested that in NPC and in about 
10% of GCs EBV exhibits an important role in tumor development and progression. Indeed, 
all EBV positive tumor cells appear to be a result of monoclonal outgrowth of one single 
infected cell (Gu et al., 2012; Iizasa et al., 2012; Li et al., 2006; Lo et al., 2004, 2012; 
Rickinson & Kieff, 2007; Takada, 2012). Nevertheless, EBV by itself does not transform 
epithelial cells in vitro. Interestingly, low-grade dysplastic precursor lesions in both NPC and 
GC have been shown to be EBV negative (Chan et al., 2000, 2002; Zur Hausen et al., 2004). 
This lead to a model where preexisting cellular alterations generate cells that are either more 
susceptible to EBV infection or are able to support a persistent latent EBV infection, 
contributing to tumor progression and malignant transformation (Gu et al., 2012; Iizasa et al., 
2012; Lo et al., 2004, 2012; Rickinson & Kieff, 2007; Tsao et al., 2012; Yoshizaki et al., 
2013). 
The oral mucosal epithelium is a dynamic tissue with a distinct multilayer architecture 
(Patel et al., 2011). Its basement membrane separates the epithelium from the underlying 
lamina propria and ensures correct and directed migration and differentiation of the overlying 
epithelial cells towards the surface of the epithelium. The stratum basale, a single layer of 
cells resting on the basement membrane, is most important for tissue hemostasis. The stratum 
basale harbors a small sub-population of epithelial stem cells, which can undergo mitotic 
division and give rise to transiently proliferating progenitor cells (Feller et al., 2013; Patel et 
al., 2011). The transiently proliferating cells then can generate daughter cells that migrate and 
differentiate through the stratum spinosum and stratum granulosum towards the epithelial 
surface, the stratum corneum. Epithelial stem cells are known to have an increased expression 
and activity of the human telomerase reverse transcriptase (hTERT), the rate-limiting 
component of the telomerase complex, to ensure indefinite proliferation and continuous self-
renewal capacity (Crowe et al., 2005; Feller et al., 2013; Kumar et al., 2005; O’Flatharta et 
al., 2002; Yasumoto et al., 1996). Due to their self-renewal capacity, these stem and 
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transiently proliferating cells might accumulate genetic and epigenetic alterations (Feller et 
al., 2013; Patel et al., 2011) and therefore acquire a precancerous phenotype. 
EBV is rapidly lost from infected primary epithelial cells or from epithelial tumor cells 
in vitro (Glaser et al., 1989; Shannon-Lowe et al., 2009; Wu et al., 2003; Yao et al., 1990). 
Nonetheless, it was possible to establish hTERT-immortalized nasopharyngeal epithelial 
(NPE) cell clones, able to support a long-term infection by EBV. It appeared that loss of the 
tumor suppressor p16, or its inactivation, and cyclin D1 overexpression are crucial for the 
establishment and the support of a stable EBV infection (Tsang et al., 2010, 2012; Yip et al., 
2013), both common events in NPC and GC development (Lee et al., 2008; Lo et al., 2004, 
2012; Nagini, 2012; Qu et al., 2013). Thus, cells with enhanced living potential seem to be 
more susceptible to EBV infection. 
EBV itself has the ability to induce telomerase activity in B-cells (Jeon et al., 2009; 
Kataoka et al., 1997; Sugimoto et al., 2004). Key player for such telomerase activity 
induction is LMP1, the major EBV-encoded oncogene. Notably, LMP1 induces telomerase 
activity via NF-κB activation in B-cells and after ectopic expression in epithelial cells (Ding 
et al., 2005; Mei et al., 2006; Terrin et al., 2008). Additionally, it was shown that hTERT 
induction contributes to EBV maintenance by induction of latent and down-regulation of lytic 
EBV gene expression in early-passage infected B lymphocytes (Terrin et al., 2007). 
Moreover, hTERT inhibition might promote lytic EBV replication in EBV-immortalized and 
fully transformed B cells (Giunco et al., 2013). Nevertheless, the impact of hTERT 
expression and telomerase activity on the EBV infection in epithelial cells remains to be 
elucidated. 
Following the current hypothesis that acquired genetic and epigenetic alterations 
within epithelial stem cells and transiently proliferating cell compartments generates an 
environment that enables a persistent EBV infection, we aimed to investigate the impact of 
hTERT expression and telomerase activity on the infection of epithelial cells. We 
hypothesized that increased telomerase activity in epithelial cells contributes also to EBV 
maintenance by supporting their infection. To prove our hypothesis, we generated epithelial 
model cell lines (i) with increased telomerase activity, by ectopic expression of hTERT, and 
(ii) with lowered telomerase activity, by ectopic expression of a catalytically inactive 
DNhTERT. Subsequently, we exposed the model cell lines to EBV assessed the frequencies 
of infection by flow cytometry and EBV gene expression by RT-qPCR. 
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IX.1.3 Material and Methods 
Cells and Viruses 
As epithelial model cell lines we used the nasopharyngeal carcinoma (NPC) cell line 
HONE-1 (Glaser et al., 1989), maintained in RPMI-1640 (Sigma-Aldrich, Buchs, 
Switzerland), the gastric carcinoma cell line AGS (Barranco et al., 1983), maintained in 
HAM’s F-12 (Sigma-Aldrich) and the human embryonic kidney cell line HEK293 (Graham et 
al., 1977), maintained in Dulbecco’s Modified Eagle’s Medium (DMEM; Sigma-Aldrich). All 
media were supplemented with 10% heat inactivated Fetal Bovine Serum (FBS; Sigma-
Aldrich), 1% L-Glutamine and 1% Penicillin/Streptomycin (Gibco, Zug, Switzerland).  
The EBV producer cell line HEK293-rB95-8 (Delecluse et al., 1998), kindly provided 
by Wolfgang Hammerschmidt, was maintained in DMEM (Sigma-Aldrich) supplemented 
with heat inactivated 10% FBS, 1% L-Glutamine, 1% Penicillin/Streptomycin, 100 µg/ml 
Hygromycin B (HygroGOLD; InvivoGen). Virus containing supernatants were obtained as 
described elsewhere (Feederle et al., 2007). Briefly, 80-90% confluent 10 cm dishes of 
HEK293-rB95-8 cells were transfected with 2 µg each of expression plasmids encoding 
BZLF1, to induce lytic replication, and BALF4 to optimize gp110 levels on the viral surface 
(Neuhierl et al., 2002) using Metafectene (Biontex, Martinsried/Planegg, Germany). Four 
hours after transfection, the transfection mixture was replaced by fresh supplemented DMEM 
without Hygromycin B. Three to four days after transfection, supernatants were harvested, 
cleared by centrifugation at 4°C with 1.000 x g for 15 min, filtered through a 0.45 µm filter 
and stored at -80°C. The number of infectious EBV units was determined as described by 
Dirmeier et al. (2003) and virus titers are given as multiplicity of infection (MOI) and defined 
as infectious units/cell (Dirmeier et al., 2003; Feederle et al., 2007). 
Generation of hTERT- and DNhTERT-overexpressing epithelial cell lines 
To generate hTERT-overexpressing we employed the expression vector pWZL-Blast-
Flag-HA-hTERT (Maida et al., 2009), kindly provided by William C. Hahn. To generate cells 
expressing the dominant negative hTERT (DNhTERT) we exchanged the hTERT insert from 
pWZL-Blast-Flag-HA-hTERT with the DNhTERT mutant from the expression vector 
pBABE-DNhTERT (Hahn et al., 1999), kindly provided by Bob Weinberg, using the 
EcoRI/SalI restriction sites. Empty control vector was generated by excision of the hTERT 
insert from pWZL-Blast-Flag-HA-hTERT, using the XhoI/SalI restriction sites and 
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subsequent re-ligation. We then transfected either 1x106 HONE-1, AGS or HEK293 cells 
with the hTERT-, DN-hTERT or the empty vector (later referred as HONE-1, AGS or 
HEK293-EV, -hT and -DN), respectively, using Metafectene and 2 days post transfection we 
selected for resistant cells and maintained the cells with the addition of 10 µg/ml Blasticidin 
(InvivoGen) to the normal growth medium to establish stable cell lines. 
Gene expression analysis by RT-qPCR 
Gene expression was determined by quantitative reverse transcription polymerase 
chain reaction (RT-qPCR) using specific primers and probes for the housekeeping gene 
hydroxymethylbilane synthase (HMBS), the non-coding EBV encoded RNA EBER1, the 
latency associated EBV genes EBNA1, EBNA2, for LMP1 and for the two genes related to the 
lytic replication cycle of EBV, BZLF1 and BXLF2, as described earlier (Dorner et al., 2008; 
Ladell et al., 2007). Gene expression of hTERT and DNhTERT was determined using a pre-
validated primer/probe assay (Hs00972656; Applied Biosystems, Zug, Switzerland). 
Therefore, total RNA was isolated 72 h post infection (p.i.) using the RNeasy Mini Kit 
(Qiagen, Hombrechtikon, Switzerland), followed by DNase treatment (DNA-free Kit; 
Ambion, Zug, Switzerland) and cDNA synthesis from 0.5 µg RNA using a High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems) according to manufacturers 
instructions. All reactions were performed in triplicates for each condition and gene on an 
ABI Prism 7700 Sequence Detection System (Applied Biosystems) using the TaqMan Gene 
Expression Master Mix (Applied Biosystems). Cycling conditions were as follows: a 10 min 
denaturation step at 95°C was followed by 40 cycles of denaturation for 15 s at 95°C and 
annealing and synthesis for 1 min at 60°C. Results were analyzed with the software SDSv2.3 
(Applied Biosystems) and gene expression was calculated relative to the housekeeping gene 
HMBS using the 2^dCt method. Cycle threshold (Ct) values from technical replicates with 
standard deviations (SD) > 0.5 were excluded from gene expression calculations. Ct values 
above 36, resulting in relative gene expression levels below 0.001, defined the limit of 
detection since these values become unreliable above this threshold. 
Western Blot analysis 
To determine Telomerase protein levels by western blot analysis, whole-cell extracts 
were prepared from 1x106 cells using RIPA buffer (50 mM Tris-Cl, pH 6.8, 100 mM NaCl, 
1% Triton X-100, 0.1% sodium dodecyl sulfate) supplemented with complete mini protease 
ATTACHMENTS 	  
	  
65 
inhibitor cocktail (Roche, Rotkreuz, Switzerland). After determination of the protein 
concentration using the Pierce BCA Protein Assay Kit (Thermo Scientific, Wohlen, 
Switzerland), protein extracts were separated on 4-12% NuPAGE Bis-Tris Precast gels 
(Invitrogen, Zug, Switzerland) and proteins were semi-dry transferred for 45 min with 25 V 
on nitrocellulose membranes (Optitran BA-S83; Whatman, Wohlen, Switzerland). hTERT 
and DNhTERT protein was probed with the primary Telomerase reverse Transcriptase 
antibody Y182 (1:500; Novus Biologicals, Luzern, Switzerland) and as loading control β-
Actin was probed with the primary β-Actin antibody (dilution 1:5000; #4967, Cell Signaling, 
Allschwil, Switzerland). Primary antibodies were detected using a horseradish peroxidase-
conjugated goat anti-rabbit IgG (dilution 1:5000; #7074, Cell Signaling). Signals were 
obtained by incubation with the SuperSignal West Femto Chemiluminescent Substrate 
(Thermo Scientific) following manufacturer instructions and visualized on the Image Reader 
LAS-3000 (Fujifilm, Tokyo, Japan). 
Telomeric repeat amplification protocol (TRAP) assay 
Telomerase activity was determined using the TRAPeze Telomerase Detection Kit 
(S7700; Millipore, Zug, Switzerland) following manufacturers instructions with following 
modifications. Protein concentrations were determined using the Pierce BCA Protein Assay 
Kit (Thermo Scientific). The reactions were carried out with 1:50 diluted cell lysates, 
corresponding to 100 cells. Telomerase extension reaction was performed at 30°C for 30 min 
followed by 2 min denaturation at 94°C and addition of 2 units Taq Polymerase per reaction. 
Amplification of the telomeric repeats was done in 30 cycles including denaturation at 94°C 
for 5 s, annealing at 55°C for 30 s, elongation at 72°C for 1 min and a final single-step 
elongation at 72°C for 5 min. TRAP reactions were separated on 10% TBE gels (Invitrogen) 
and products were visualized after staining with SYBR Green I nucleic acid gel stain, 
according to manufacturers instructions (Sigma-Aldrich) using the GeneFlash gel 
documentation system (Syngene, Châtel-St-Denis, Switzerland). 
Direct infection of epithelial cells with cell-free virus by spinoculation 
For the direct infection of epithelial cells with cell-free virus we employed an adapted 
spinoculation protocol to achieve measurable rates of infection (Dorner et al., 2008). Briefly, 
1x105 cells were seeded in 12-well plates (TPP, Trasadingen, Switzerland) and incubated over 
night at 37°C with 5% CO2. Target cells were then infected, by adding cell-free rB95-8 
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supernatant with varying MOIs, as indicated, to the target cells in a total volume of 500 μl	  to	  ensure	  equal	  virus	  concentrations. Then cells were centrifuged for 1 h at 32°C with 800 x 
g, supernatant was aspirated, replaced by 1 ml fresh medium and incubated for 72 h at 37°C 
with 5% CO2. To determine infection frequencies,	  cells were detached 72 h p.i., using 0.25% 
Trypsin-EDTA (Gibco), washed with 1x phosphate buffered saline (PBS; Gibco), stained	  with 
the cell viability dye 7-Amino-Actinomycin D (7-AAD; BD Bioscience, Allschwil, 
Switzerland), to exclude non-viable cells, according to manufacturer’s instructions. After one 
wash with 1x PBS the amount of GFP positive (infected cells) was determined by flow 
cytometry using the FACS Canto II (BD Bioscience) within the living cell population. Mock 
infections of each cell line were performed without virus and the amount of GFP positive 
cells detected as background signals were subtracted (-mock) from corresponding infections. 
Statistical analysis 
Data sets were tested for statistical significance as indicated using Prism6 (GraphPad, 
La Jolla, CA, USA) and P values <0.05 were regarded as statistically significant. 
IX.1.4 Results 
Generation of epithelial cell lines with increased telomerase expression or expression of 
the dominant negative telomerase mutant 
To address the question whether hTERT expression level contributes to EBV infection 
in epithelial cells, we first established an in vitro model using three EBV-negative epithelial 
cell lines: the NPC cell line HONE-1, the gastric carcinoma cell line AGS and the standard 
epithelial model cell line HEK293. The cells were transfected either with an expression vector 
encoding for hTERT (hT), the rate limiting component of the human telomerase complex, the 
telomerase reverse transcriptase, or for its catalytically inactive mutant DNhTERT (DN) 
(Hahn et al., 1999), respectively. Cells transfected with the empty vector (EV) served as 
control. After transfection, cells were selected for stable integration. 
To confirm overexpression in hTERT and DNhTERT transfected cells, we first 
investigated gene and protein expression (Fig. 1). Compared to EV control cells, we observed 
increased hTERT and DNhTERT gene expression in HONE-1 cells by 92.95 ± 13.07 and 
106.03 ± 30.16 fold, respectively; in AGS cells 20.87 ± 4.71 and 25.69 ± 9.14 fold, 
respectively; and in HEK293 cells 162.72 ± 28.84 and 153.34 ± 31.82, respectively (Fig. 1A). 
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Western blot quantification of protein expression (Fig. 1B) indicated increased protein 
expression of hTERT and DNhTERT in HONE-1, AGS, and HEK293 cells in good 
agreement with the increased gene expression. 
 
 
 
 
 
 
 
 
 
Increased hTERT expression leads to increased telomerase activity, which is suppressed 
upon expression of the catalytically inactive, dominant negative mutant DNhTERT 
After having confirmed overexpression of hTERT and DNhTERT in the engineered 
cell lines, we asked how hTERT and DN-hTERT expression impacts on telomerase activity. 
To assess telomerase activity in the epithelial model cell lines, we employed the Telomeric 
Repeat Amplification Protocol (TRAP assay). Figure 2A shows the results of a representative 
assay. Endogenous telomerase activity was readily detected in all three EV control cell lines 
(Fig. 2B). Nevertheless, compared to the robust increase of gene and protein expression, the 
ectopic expression of hTERT led to a modest increase of telomerase activity in HONE-1-hT 
(104.8% ± 15.8 of EV control) and HEK293-hT (115.0% ± 0.1 of EV control) cells compared 
to the EV controls. This might be due to an endogenous already high telomerase activity of 
wild type cancer cells leading to non-optimal assay conditions as exemplified by the weak 
standard internal control (S-IC) in HEK293-EV and -hT cells due to the competitive nature of 
the assay (Fig. 2A). The telomerase activity in AGS-hT cells was increased to 222.5% ± 49.9 
of EV-control cells. The expression of DNhTERT led to suppression of telomerase activity 
below endogenous levels in all three cell lines with the strongest reduction observed in 
Figure 1: hTERT and DNhTERT expression 
in epithelial cell lines. A) hTERT and 
DNhTERT mRNA levels were determined in 
empty vector control (EV; white), in hTERT 
(hT; grey) and dominant negative hTERT (DN; 
black) overexpressing  cells by RT-qPCR 
relative to HMBS and shown as fold change 
over  EV. Data is shown as Mean ±SD of 3 
independent experiments. * = p<0.05; ** = 
p<0.01; *** = p<0.001 (ordinary one-way 
ANOVA; Dunnett’s multiple comparison test). 
B) Protein expression was confirmed by 
western blot using β-Actin as loading control. 
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HONE-1-DN cells (24.1% ± 18.0 of EV control) followed by HEK293-DN cells (52.3% ± 
0.02 of EV control) and AGS-DN cells (60.1% ± 12.2 of EV control). Taken together, 
expression of hTERT or DNhTERT was significantly increased in all stable cell lines. 
However, telomerase activity was markedly increased only in AGS-hT cells, as measured by 
the TRAP assay. The expression of the DNhTERT led to consistent decrease of telomerase 
activity of about 50% in all three stable cell lines. 
 
 
 
 
 
 
 
 
Increased hTERT expression and activity correlates in part with the infection of 
epithelial cells by EBV 
After establishment of stably hTERT- and DNhTERT-overexpressing cell lines we 
investigated the impact of hTERT expression and telomerase activity on the infection of these 
epithelial model cell lines. Therefore, we performed infection studies using a recombinant, 
wild type EBV strain, rB95-8, that carries a green fluorescent protein (GFP) and allows 
identification of infected cells by determining GFP expression (Delecluse et al., 1998). We 
infected the cells using a spinoculation protocol (Dorner et al., 2008) with varying MOIs and 
determined the amount of infected cells 72h p.i. by flow cytometry as shown in Figure 3. 
The EBV-negative cell line HONE-1 originates from an EBV-positive NPC that has 
lost EBV in vitro (Glaser et al., 1989; Yao et al., 1990). Surprisingly, there was no 
measurable infection (<0.05% GFP positive cells) of the three stable HONE-1 cell lines (Fig. 
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Figure 2: Relative telomerase activity in epithelial cell lines. Telomerase activity in the epithelial cell lines 
HONE-1, AGS and HEK293 was determined by TRAP assay (A; representative assay) in empty vector (EV) 
control, in hTERT (hT) and dominant negative hTERT (DN) overexpressing cells and shown relative to EV (B). 
Data is represented as Mean ± SD from triplicate measurements; S-IC = standard internal control; PC = positive 
control; NC = negative control; h.i. = heat inactivated. 
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3A), indicating that the infection of epithelial cells may be dependent on the cellular context 
and on clonal effects in vitro as suggested by Glaser et al. (Glaser et al., 1989). 
AGS cells showed in general low EBV infection frequencies, depending on MOI, 
ranging from 0.02 ± 0.03 to 2.51% ± 0.33 (Fig. 3B). Using MOIs of 0.5 and 1, we observed 
significantly increased infection frequencies of AGS-hT (0.47% ± 0.05 and 0.46% ± 0.03) 
compared to AGS-EV control cells (0.30% ± 0.008 and 0.20% ± 0.09). Surprisingly, with 
further increase of EBV dose (MOI 2.5) AGS-hT cells showed a lower infection frequency 
compared to AGS-EV cells (2.06% ± 0.16 vs. 2.51% ± 0.33) but the difference was not 
significant. The expression of the dominant negative hTERT mutant and therefore the 
suppression of telomerase activity in AGS-DN cells inhibited the infection of these cells 
completely, at least for MOIs of 0.5 (0.02% ± 0.07) or 1 (0.02% ± 0.03). The infection with 
MOI 2.5 resulted in a further increased infection frequency of AGS-DN cells, but that still 
was lower compared to that of EV control cells (0.55% ± 0.14 vs. 2.51% ± 0.33; p<0.0001). 
These results indicate that the infection of AGS cells by EBV at low MOIs is dependent on 
telomerase activity and suggest a contribution of telomerase activity to increased 
susceptibility to infection by EBV or more likely to support of EBV replication and 
maintenance in AGS cells. 
The infection frequencies in HEK293 cells were in general quite robust and ranged 
from 1.85% ± 0.2 to 10.84% ± 0.93 as shown in Figure 3C. Upon infection with MOI 0.5 
HEK293-EV, -hT and –DN cells showed infection frequencies of 1.85% ± 0.2, 2.05% ± 0.11 
and 2.23% ± 0.19, respectively, without significant difference between various hTERT 
expression and telomerase activity levels. Upon infection with higher MOIs of 1 and 2.5 we 
did see increased infection frequencies for HEK293-hT (3.96% ± 0.09 and 10.84% ± 0.93) 
cells compared to the EV control cells (2.32% ± 0.12 and 7.36% ± 0.54). To our surprise, we 
found as well significantly increased infection rates of HEK293-DN cells (3.89% ± 0.19 and 
9.11% ± 0.49) compared to HEK293-EV control cells upon an infection with MOI 1 and 2.5. 
These results indicate that the infection of HEK293-hT is dependent on telomerase activity. 
The infections of HEK293-DN cells additionally indicate that activity-independent telomerase 
functions might potentially be involved in the infection of epithelial cells. 
Taken together, we observed, at least partially, augmented EBV infection frequencies 
of epithelial cells with increased hTERT expression levels and therefore increased telomerase 
activity and decreased infection frequencies in cells with reduced telomerase activity. These 
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results suggest that cells with higher telomerase activity are either more susceptible to an 
infection by EBV or that increased telomerase activity supports EBV maintenance in 
epithelial cells and that activity-independent telomerase functions might potentially contribute 
to the infection of epithelial cells by EBV. These effects, however, seemed to be strongly 
dependent on the amount of EBV and especially on the cellular background, since HONE-1 
cells were in general not susceptible to an infection by EBV and the infection frequencies of 
HEK293 cells were consistently at least 2-fold higher compared to AGS cells at the 
corresponding MOI. 
 
 
 
 
 
 
 
Telomerase activity supports infection of epithelial cell lines by EBV by enhancing EBV 
gene expression 
Upon infection with rB95-8, the expression of GFP is driven by the constitutive CMV 
promoter (Delecluse et al., 1998). GFP expression does not necessarily indicate infection of 
the cell since it might be expressed independently of EBV gene expression or replication. As 
a second indication for an ongoing infection of these cells and to further investigate the 
impact of telomerase activity, we determined the EBV gene expression in our epithelial model 
cell lines.  Therefore, we investigated the expression of the non-coding RNA EBER1, of three 
latency-associated genes EBNA1, EBNA2 and LMP1 as well as the immediate-early lytic gene 
BZLF1 and the late lytic gene BXLF2. EBV gene expression was determined in AGS cells and 
HEK293 cells upon infection at MOI 2.5 as shown in Figure 4A and B, respectively, since we 
obtained the most robust infections at this MOI and the infection in HONE-1 cells was at the 
limit of detection or below. 
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Figure 3: Infection frequencies of epithelial cell lines. The amount of infected (in %GFP positive) HONE-1 
(A), AGS (B) and HEK293 (C) cell lines was determined within the living cell (7-AAD negative) population by 
flow cytometry 72h p.i. after subtraction of the background signal obtained from mock infected cells (-mock). 
Data is represented as Mean ± SD of 3 independent infections. EV control cells = white; hT = grey; DN = black; 
* = p<0.05; ** = p<0.01; *** = p<0.001; **** = p<0.0001 (ordinary one-way ANOVA; Dunnett’s multiple 
comparison test). 
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Expression of all EBV genes tested in our panel and of EBER1 was detected in cells 
from all six cell lines. The most abundant transcripts in the AGS cells were EBNA1 and in the 
HEK293 cells EBER1 (relative expression data not shown). 
Increased hTERT expression and telomerase activity in AGS-hT cells led to increased 
transcription of all EBV genes including EBER1 with the exception of BZLF1 that was 
reduced to 0.65-fold of EV control cells. LMP1 showed the strongest increase of expression 
with a 5.43-fold up-regulation compared to EV control cells. The expression of EBNA2 (2.5-
fold) and BXLF2 (1.97-fold) was as well significantly up-regulated in comparison to AGS-EV 
cells. Suppression of telomerase activity in AGS-DN cells resulted in lower expression of all 
genes except of LMP1 compared to EV control cells. BZLF1 expression (0.08-fold) was 
significantly lower in AGS-DN and LMP1 (1.02-fold) was transcribed at a similar level in 
comparison to AGS-EV cells. The expression of hTERT in HEK293-hT cells led as well to 
the up-regulation of all EBV genes tested and LMP1 showed the strongest and most 
significant up-regulation of 2.74-fold over EV control cells. Additionally, expression of 
EBNA1 (1.69-fold), EBNA2 (1.97-fold) and BXLF2 (1.99-fold) was significantly up-regulated 
in HEK293-hT cells compared to HEK293-EV cells. EBV gene expression in HEK293-DN 
cells was comparable to EV control cells, showing as well that increased telomerase activity 
contributes to EBV gene expression in HEK293 cells. 
 
 
 
 
 
 
 
 
 
 
Figure 4: EBV gene expression in epithelial cells upon infection. EBV gene expression was determined in 
AGS (A) and HEK293 (B) empty vector control (EV; white), in hTERT (hT; grey) and in dominant negative 
hTERT (DN; black) cells, respectively, 72h p.i. at MOI 2.5 by RT-qPCR relative to HMBS and shown as fold 
change over EV control. Data is represented as Mean ± SD of 3 independent infections; * = p<0.05; ** = 
p<0.01; *** = p<0.001 (ordinary one-way ANOVA; Dunnett’s multiple comparison test). 
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Taken together, these results indicate that the expression of EBV genes is depending 
on telomerase activity in our epithelial model cell lines AGS and HEK293. However, only in 
AGS-DN cells the suppression of telomerase activity did lead to down-regulation of EBV 
gene expression but not to increased expression of BZLF1 as shown by others (Giunco et al., 
2013; Terrin et al., 2007) in EBV positive Burkitt’s lymphoma and lymphoblastoid cell lines. 
This suggests a contribution of telomerase activity to latent EBV replication and maintenance 
by enhancing EBV gene expression in epithelial cells. 
IX.1.5 Discussion 
In this study we generated in vitro model systems to study the impact of increased 
hTERT expression and telomerase activity on the infection of epithelial cells by EBV. We 
found that increased telomerase activity contributes to the EBV infection of epithelial cells. 
Our data indicate that i) increased telomerase activity can contribute to the infection of 
epithelial cells; ii) increased telomerase activity can generate an environment facilitating EBV 
replication as shown at gene expression level with increased EBV gene expression in hTERT-
overexpressing cells, and iii) the infection of epithelial cells is strongly dependent on the 
cellular context and might be even more dependent on clonal effects in vitro. This is the first 
study showing that EBV gene expression is enhanced by increased telomerase activity, 
mediated through ectopic expression of hTERT. 
We increased hTERT expression and telomerase activity in the epithelial model cell 
lines by transfection and selection for stable integration. In contrast to the strong increase of 
hTERT expression at mRNA and protein level in all three hT-cell lines, telomerase activity in 
HONE-1-hT and HEK293-hT was slightly increased, most likely due to the relatively high 
endogenous telomerase activity. These results are in line with the findings of Hahn and 
colleagues, showing slightly increased telomerase activity upon expression of hTERT in 
telomerase positive cancer cell lines (Hahn et al., 1999) 
Although suppression of telomerase activity below endogenous levels was achieved in 
all DN-cell lines, we could not fully block telomerase activity through the expression of the 
catalytically inactive DNhTERT mutant and did not observe an inhibiting effect on cell 
proliferation as in contrast demonstrated by Hahn et al. (Hahn et al., 1999). All stable 
DNhTERT expressing cell lines showed similar growth behavior in culture compared to their 
corresponding EV control and hTERT cells. However, we did not select for single cell clones 
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but rather used the whole pool of stably transfected cells for our experiments. This might have 
resulted in more heterogeneous expression levels within the pool of stably transfected cells 
compared to clonal populations. Cell clones with sufficient amounts of DNhTERT, to 
completely block telomerase activity, might indeed stop proliferating and eventually become 
apoptotic (Hahn et al., 1999). These cells are therefore potentially lost during the selection 
procedure. As shown by Hahn and colleagues (Hahn et al., 1999), we did as well observe 
single cells with characteristic large and flattened crisis associated morphology in the stably 
DNhTERT-transfected cell lines, especially in AGS-DN cells, indicating presumably cells 
that stopped proliferating. However, the number of cells with this appearance was not 
significantly different from corresponding EV or hT cultures. 
The infection studies of the epithelial model cell lines revealed a quite heterogeneous 
infection pattern. First, infection of HONE-1 cells was not achieved in our experimental 
setup, which is not very surprising since it has been shown that the originally EBV-harboring 
cell line HONE-1 had lost its susceptibility to direct infection in vitro (Glaser et al., 1989), 
indicating that the infection of epithelial cells may depend on the cellular context and on 
clonal effects.  Additionally, Tsang and colleagues (Tsang et al., 2010) showed infection of 
HONE-1 cells by cell-to-cell contact with EBV positive and lytically induced BL cells, 
indicating a distinct mode of infection in nasopharyngeal cells. For further studies it will be 
important to employ a cell-to-cell contact infection protocol to investigate the impact of 
telomerase activity on the EBV infection of HONE-1 cells. 
The infection of AGS and HEK293 cells confirmed the strong dependence on the 
cellular background since infection frequencies in HEK293 cells were in general at least 2-
fold higher then in AGS cells. We observed that in AGS cells hTERT expression and 
therefore increased telomerase activity can contribute to modulate EBV infection, as shown 
by increased infection frequencies in AGS-hT cells at low MOIs and inhibited or impeded 
infections in cells expressing the catalytically inactive DNhTERT mutant. These results 
suggest a contribution of telomerase activity to either increase susceptibility to infection or to 
foster the establishment of an environment supporting EBV replication and maintenance. 
Increased infection frequencies of HEK293-DN cells compared to EV control cells 
additionally indicate that hTERT activity independent effects might also influence infection 
rates. For example hTERT was shown to act as transcriptional modulator of the Wnt/β-
catenin pathway (Park et al., 2009) that in turn might modulate expression of a putative 
receptor for EBV binding or entry into epithelial cells. To add another level of complexity to 
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the whole story, the infection efficiency itself and the effect of hTERT on the infection are 
dependent on the viral dose. Probably, the maximum level of infection of AGS cells was 
exceeded with MOI 2.5, as suggested by the decreasing differences observed between AGS-
EV and AGS-hT and by the increased infection frequencies of AGS-DN cells. We expected 
that infection studies with higher MOIs on HEK293 cells would have revealed pronouncedly 
enhanced infection frequencies due to hTERT expression and telomerase activity in these 
cells, but this was not the case. We feel that in this context, the gastric carcinoma cell line 
AGS represents a more physiological model better reflecting the in vivo situation than 
HEK293 cells, given that GC may be associated with EBV. 
The investigation of EBV gene expression in AGS and HEK293 cells revealed that the 
infection is more of latent nature although we detected expression of BZLF1, the master 
regulator of lytic EBV replication induction, and a certain amount of BXLF2 gene expression, 
a late lytic EBV gene. We expected lower expression of BZLF1 in hTERT-overexpressing 
cells, and this was observed in AGS-hT but not in HEK293-hT cells. Moreover, we expected 
increased expression in cells with suppressed telomerase activity since it was shown that 
hTERT expression inhibits lytic EBV replication and that hTERT silencing leads to increased 
BZLF1 gene expression in B-cells (Giunco et al., 2013; Terrin et al., 2007). However, we did 
not observe increased BZLF1 expression upon suppression of telomerase activity, probably 
because of the low infection frequencies in AGS-DN cells and the relatively high remaining 
endogenous telomerase activity in HEK293-DN cells. On the other hand, BZLF1 expression 
was reported in hTERT-immortalized primary NPE cells but was rapidly lost early after 
infection and was very low or undetectable in these stably EBV-infected NPE cell lines 
(Tsang et al., 2010, 2012; Yip et al., 2013). We would expect this to happen as well with 
further propagation of our infected cells. Except BZLF1, all other EBV genes were up-
regulated in both AGS-hT and HEK293-hT cells, while suppression of telomerase activity led 
to lower expression of EBV genes at least in AGS-DN cells. This confirms that telomerase 
activity contributes to the establishment and maintenance of the EBV infection in epithelial 
cells through up-regulation mainly of latency associate EBV genes. 
A major limitation of our study is that we used transformed cell lines instead of 
primary epithelial cells to establish the model system. The vast majority of cancer cell lines as 
well as primary tumors possess a certain amount of telomerase activity, which is a hallmark of 
cancer (Hanahan & Weinberg, 2011, 2000). So do our epithelial model cell lines, since 
hTERT was already endogenously expressed and telomerase activity was detectable in these 
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model cell lines. However, we are convinced that at least the cell line AGS is suitable to study 
the impact of telomerase activity on the infection of epithelial cells since they posses a 
relatively low endogenous telomerase activity and other common features of NPC and GC 
like cyclin D1 expression and lack of p16 expression (Li et al., 2012; Mattioli et al., 2007). 
Another limitation of this study might be that we only used one virus strain for the infection 
of epithelial cells. Very recently, another EBV strain called M81, isolated from a Chinese 
patient with NPC, was described (Tsai et al., 2013). In contrast to the common laboratory 
wild type EBV strains B95-8 and Akata, M81 exhibits an enhanced tropism for epithelial cells 
and a preference for lytic replication but is still able to transform B-cells efficiently. With 
regard to NPC, using this strain for the infection experiments would be more physiological to 
study the infection of epithelial cells with enhanced telomerase expression and activity. 
Additionally, we would expect more robust infection frequencies and EBV gene expression 
upon infection with M81. This would potentially reveal more pronounced effects of hTERT 
expression and telomerase activity on the infection of epithelial cells by EBV and its 
contribution to EBV maintenance. 
Our findings contribute to the current hypothesis that EBV may be able to infect 
epithelial cells but that there are additional factors needed, e.g. chromosomal aberration, 
genetic and epigenetic alteration or dysregulated cell signaling pathways, to render them 
permissive for a latent EBV infection and that the infection by EBV is a late event in the 
development of EBV associated epithelial cell carcinomas (Fukayama & Ushiku, 2011; Zur 
Hausen et al., 2004; Iizasa et al., 2012; Lo et al., 2012; Tsang et al., 2012; Tsao et al., 2012; 
Yoshizaki et al., 2013; Young & Rickinson, 2004). Based on this hypothesis and our results 
we speculate that enhanced EBV gene expression supported by increased telomerase activity 
drives malignant transformation and tumor progression in epithelial cells. We further 
hypothesize that hTERT and EBV cooperate in a positive feedback loop since EBV itself can 
induce telomerase activity. That would lead in turn to promotion of latent EBV infection and 
the expression of latent gene products, such as LMP1 and LMP2A. The expression of latent 
proteins will then facilitate rapid clonal expansion and transformation thus favoring further 
accumulation of genetic alteration and epigenetic changes and ultimately contribute to 
malignant transformation and tumor progression. 
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IX.2.1 Abstract 
The ubiquitous γ-herpesvirus EBV is very successful in infecting >90% of the human 
population. EBV is transmitted via saliva to the next susceptible host and thus the pharyngeal 
cavities are portal of entry and exit for Epstein-Barr virus (EBV). Various microbes with 
specific pathogen associated molecular patterns (PAMPs) constantly challenge the oral 
mucosal epithelial tissues lining the pharyngeal cavities. As a first line of defense, the innate 
immune system recognizes these microorganisms via pattern recognition receptors (PRRs) 
such as Toll-like receptors (TLRs). Signaling triggered by TLR stimulation results in 
expression of pro-inflammatory cytokines, chemokines and anti-microbial effector molecules 
and is therefore contributing to shape the adaptive immunity as a second response to invading 
pathogens. Apart from the mechanical and physical barrier function of pharyngeal epithelial 
cells, they express TLRs and are capable of mounting an innate immune response. Thus 
epithelial cells of the pharyngeal cavity play a pivotal role not only within the life cycle of 
EBV. Recently we have demonstrated that TLR9 activation can suppress the reactivation 
from latent to lytic EBV infection in EBV positive Burkitt’s lymphoma cells whereas 
triggering of TLR2 in latently infected lymphoblastoid cell lines elicits lytic EBV replication. 
However, the impact of activated TLR signaling on the infection of epithelial cells by EBV 
remains elusive. Therefore, we investigated the effect of TLR9 stimulation on EBV infection 
of epithelial cells. Here, we show that TLR9 triggering with synthetic ligands has no impact 
on EBV infection of the stably TLR9-expressing epithelial model cell line HEK293 and its 
wild type counterpart. Additionally, our results indicate that both cell lines might actually not 
be suitable as epithelial cell models to study the effect of TLR signaling on the infection of 
epithelial cells by EBV, but they suggest a contributing role of TLR activation in epithelial 
cells to EBV reactivation from latency. 
IX.2.2 Introduction 
Epstein-Barr virus (EBV) is a member of the γ-herpesvirus family that is transmitted 
via saliva between human hosts (Rickinson & Kieff, 2007). The infection by EBV is usually 
asymptomatic if acquired during early childhood and may cause infectious mononucleosis 
(IM) if acquired later in life (Rickinson & Kieff, 2007). Apart from IM, EBV is irrefutably 
linked to various lymphoid and epithelial cell malignancies, e.g. Burkitt’s lymphoma (BL), 
gastric carcinoma (GC) and nasopharyngeal carcinoma (NPC) (Rickinson & Kieff, 2007). 
Following primary infection, EBV persists life-long within the host B cell pool. Once the B 
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cells are infected, EBV establishes a latent infection with limited gene expression and 
therefore a maximum level of immune evasion (Griffin et al., 2010; Hislop et al., 2007; Kieff 
& Rickinson, 2007; Speck & Ganem, 2010; Taylor & Blackbourn, 2011). Nevertheless, EBV 
has to undergo lytic replication to produce infectious progeny virus that can be shed into 
saliva. Lytic EBV replication potentially takes place within permissive epithelial cells of the 
oropharynx (Rickinson & Kieff, 2007). 
As EBV transmission occurs via saliva, the pharyngeal cavities are the portal of entry 
and exit for EBV (Rickinson & Kieff, 2007). Thus, the pharyngeal epithelium is the first 
barrier that EBV has to overcome to get access to the B lymphocytes, its target cells for life-
long persistence. Various microorganisms constantly challenge the pharyngeal epithelium 
(Diamond et al., 2008; Feller et al., 2013). Thus, innate immune mechanisms play an 
important role in the local defense in addition to the mechanical and physical barrier function 
of epithelial cells. Microbial invaders own specific pathogen associated molecular patterns 
(PAMPs) that are sensed by so called pattern recognition receptors (PRRs). Amongst these, 
Toll-like receptors (TLRs) were first PRRs to be identified and are fundamental sensors 
recognizing a wide range of PAMPs (Kawai & Akira, 2011). 
Several studies have shown that epithelial cells, including those of tonsils and upper 
airways, express TLRs and are capable of mounting innate immune responses (Claeys et al., 
2003; Hornef & Bogdan, 2005; Lange et al., 2009a; Sha et al., 2004; Swaminathan et al., 
2013; Vandermeer et al., 2004), which influence and prime the subsequent adaptive 
immunity. EBV itself was shown to activate and modulate TLR2, 3, 7, and 9 signaling in 
various cell types (Ariza et al., 2009; Fiola et al., 2010; Gaudreault et al., 2007; Iwakiri et al., 
2009; Martin et al., 2007; Vérillaud et al., 2012; West et al., 2012). Additionally, we recently 
demonstrated that activation of TLR9 signaling drives EBV into latency upon primary 
infection in B cells and inhibits the switch to lytic replication in EBV positive BL cells 
(Ladell et al., 2007; Zauner et al., 2010). More recently, our group demonstrated that in 
contrast to TLR9 activation, ligation of TLR2 with heat-killed group A streptococci (GAS) 
can induce lytic EBV reactivation in latently infected lymphoblastoid cell lines (LCLs), 
established from tonsillar mononuclear cells (TMCs) (Ueda et al., 2014). However, the 
impact of TLR signaling on EBV infection in epithelial cells remains elusive. Therefore, we 
employed two epithelial model cell lines to investigate the influence of TLR9 signaling on the 
infection of epithelial cells by EBV. 
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IX.2.3 Material and Methods 
Cells and Viruses 
As epithelial model cell lines we employed the human embryonic kidney cell line 
HEK293 (Graham et al., 1977) and HEK293XL-hTLR9-HA cells from InvivoGen (Toulouse, 
France). Both cell lines were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM; 
Sigma-Aldrich, Buchs Switzerland), supplemented with 10% heat inactivated Fetal Bovine 
Serum (FBS; Sigma-Aldrich), 1% L-Glutamine and 1% Penicillin/Streptomycin (Gibco, Zug, 
Switzerland). HEK293XL-hTLR9-HA cells are engineered to stably express human TLR9 
gene with an influence hemaglutinine (HA) tag and are therefore maintained with the addition 
of 10 µg/ml Blasticidin (InvivoGen) in the growth medium. HEK293 and HEK293XL-
hTLR9-HA cells are later referred as 293-WT and 293-TLR9, respectively. 
The EBV producer cell line HEK293-rB95-8 (Delecluse et al., 1998), kindly provided 
by Wolfgang Hammerschmidt, was maintained in DMEM (Sigma-Aldrich) supplemented 
with heat inactivated 10% FBS, 1% L-Glutamine, 1% Penicillin/Streptomycin, 100 µg/ml 
Hygromycin B (HygroGOLD; InvivoGen). Virus containing supernatants were obtained as 
described elsewhere (Feederle et al., 2007). Briefly, 80-90% confluent 10 cm dishes of 
HEK293-rB95-8 cells were transfected with 2 µg each of expression plasmids encoding 
BZLF1, to induce lytic replication, and BALF4 to optimize gp110 levels on the viral surface 
(Neuhierl et al., 2002) using Metafectene (Biontex, Martinsried/Planegg, Germany). Four 
hours after transfection, the transfection mixture was replaced by fresh supplemented DMEM 
without Hygromycin B. Three to four days after transfection, supernatants were harvested, 
cleared by centrifugation at 4°C with 1.000 x g for 15 min, filtered through a 0.45 µm filter 
and stored at -80°C. The number of infectious EBV units was determined as described by 
Dirmeier et al. (2003) and virus titers are given as multiplicity of infection (MOI) and defined 
as infectious units/cell (Dirmeier et al., 2003; Feederle et al., 2007). 
Gene expression analysis by RT-qPCR 
Gene expression was determined by reverse transcription quantitative polymerase 
chain reaction (RT-qPCR) using specific primers and probes for the housekeeping gene 
hydroxymethylbilane synthase (HMBS), for IL-6 and TNF-α, the non-coding EBV encoded 
RNA EBER1 and the viral genes EBNA1, EBNA2, LMP1, BZLF1 and BXLF2 as described 
earlier (Bonanomi et al., 2003; Dorner et al., 2008; Ladell et al., 2007). TLR1-9 gene 
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expression was determined using pre-validated primer/probe sets (Hs00413978; Hs00610101; 
Hs01551078; Hs00152939; Hs00152825; Hs01039989; Hs01933259; Hs00152972; 
Hs00152973; Assay-on-demand; Applied Biosystems, Zug, Switzerland). Briefly, total RNA 
was isolated 24 h, 48 h and 72 h post infection (p.i.) using the RNeasy Mini Kit (Qiagen, 
Hombrechtikon, Switzerland), followed by DNase treatment (DNA-free Kit; Ambion, Zug, 
Switzerland) and cDNA synthesis from 0.5 µg RNA using a High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems) according to manufacturers instructions. All reactions 
were performed in triplicates for each condition and gene on an ABI Prism 7700 Sequence 
Detection System (Applied Biosystems) using the TaqMan Gene Expression Master Mix 
(Applied Biosystems). Cycling conditions were as follows: a 10 min denaturation step at 
95°C was followed by 40 cycles of denaturation for 15 s at 95°C and annealing and synthesis 
for 1 min at 60°C. Results were analyzed with the software SDSv2.3 (Applied Biosystems) 
and gene expression was calculated relative to the housekeeping gene HMBS using the 2^dCt 
method. Cycle threshold (Ct) values from technical replicates with standard deviations (SD) > 
0.5 were excluded from gene expression calculations. Ct values above 36, resulting in relative 
gene expression levels below 0.001, defined the limit of detection since these values become 
unreliable above this threshold. 
Western Blot analysis 
hTLR9-HA protein expression was verified by western blot analysis. Therefore, 
whole-cell extracts were prepared from 1x106 cells using Radio-immunoprecipitation assay 
buffer (RIPA; 50 mM Tris-Cl, pH 6.8, 100 mM NaCl, 1% Triton X-100, 0.1% sodium 
dodecyl sulfate) supplemented with complete mini protease inhibitor cocktail (Roche, 
Rotkreuz, Switzerland). After determination of the protein concentration with the Pierce BCA 
Protein Assay Kit (Thermo Scientific, Wohlen, Switzerland), protein extracts were separated 
on 4-12% NuPAGE Bis-Tris Precast gels (Invitrogen, Zug, Switzerland) and proteins were 
semi-dry transferred for 45 min with 25 V on nitrocellulose membranes (Optitran BA-S83; 
Whatman, Wohlen, Switzerland). HA-tagged hTLR9 protein was probed with the primary 
Anti-HA Tag antibody (05-904; 1:1000; Millipore, Zug, Switzerland) and as loading control 
β-Actin was probed with the primary β-Actin antibody (dilution 1:5000; #4967, Cell 
Signaling, Allschwil, Switzerland). Primary Anti-HA antibodies were detected using a 
horseradish peroxidase-conjugated horse anti-mouse IgG (dilution 1:5000; #7076, Cell 
Signaling) and primary β-Actin antibodies were detected using a horseradish peroxidase-
conjugated goat anti-rabbit IgG (dilution 1:5000; #7074, Cell Signaling). Signals were 
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obtained by incubation with the SuperSignal West Femto Chemiluminescent Substrate 
(Thermo Scientific) following manufacturer instructions and visualized on the Image Reader 
LAS-3000 (Fujifilm, Tokyo, Japan). 
Direct infection of epithelial cells with cell-free virus by spinoculation 
For the direct infection (DI) of epithelial cells with cell-free virus we employed an 
adapted spinoculation protocol to achieve measurable rates of infection (Dorner et al., 2008). 
Briefly, 1x105 cells were seeded in 12-well plates (TPP, Trasadingen, Switzerland) and 
incubated over night at 37°C with 5% CO2. Target cells were then infected, by adding cell-
free rB95-8 supernatant (MOI 0.5) to the target cells in a total volume of 500 µl to ensure 
equal virus concentrations. Then cells were centrifuged for 1 h at 32°C with 800 x g, 
supernatant was aspirated, replaced by 1 ml fresh medium and incubated for 72 h at 37°C 
with 5% CO2. To determine infection frequencies, cells were detached 72 h p.i., using 0.25% 
Trypsin-EDTA (Gibco), washed with 1x phosphate-buffered saline (PBS; Gibco), stained 
with the cell viability dye 7-Amino-Actinomycin D (7-AAD; BD Bioscience, Allschwil, 
Switzerland), to exclude non-viable cells, according to manufacturer’s instructions. After one 
wash with 1x PBS the amount of GFP positive (infected cells) was determined by flow 
cytometry using the FACS Canto II (BD Bioscience) within the living cell population. Mock 
infections of each cell line were performed without virus and the amount of GFP positive 
cells detected as background signals were subtracted from corresponding infections. 
TLR9 stimulation with synthetic agonists 
To trigger TLR9 synthetic human TLR9 agonists containing CpG motifs were 
employed. Cells were stimulated with 1 µM of either ODN2006 (Class B; CpG-B) or 
ODN2216 (Class A; CpG-A) both from InvivoGen and the response to TLR9 stimulation was 
determined after 1 h, 2 h, 4 h and 6 h of stimulation by means of IL-6 and TNF-α gene 
expression using RT-qPCR. When cells were subjected to DI, cells were stimulated for 2h 
prior to spinoculation and ODNs were repeatedly added 24h and 48h p.i.. In total 72h p.i., the 
amount of GFP positive cells was determined by flow cytometry within the living cell 
population as mentioned above. Cells treated with endotoxin-free water, the solvent for CpG-
A and -B, served as mock control for the stimulation. 
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Statistical analysis 
Data is reported as mean ± SD from at least three independent replicates and statistical 
tests, as indicated, were computed using Prism6 (GraphPad, La Jolla, CA, USA) from at least 
3 independent experiments. P values <0.05 were regarded as statistically significant. 
IX.2.4 Results 
TLR expression in wild type and TLR9-engineered HEK293 cells 
Wild type HEK293 cells express TLR3 and 5 (Huang et al., 2009; Simon & Samuel, 
2007; Smith et al., 2003) and are devoid of TLR2 and 4 (Erridge et al., 2007; Latz et al., 
2002). It has been reported as well that TLR7, 8, 9 are not expressed in HEK293 wild type 
cells (Wang et al., 2006) while others detected TLR9 mRNA in these cells (Assaf et al., 
2009). 
Since both HEK293 cell lines, 293-WT and 293-TLR9, were obtained from two 
different sources, we first characterized their endogenous TLR gene expression patterns (Fig. 
1). We determined TLR1-9 expression by RT-qPCR relative to the housekeeping gene HMBS. 
293-WT cells expressed low levels of TLR1, 3, 5, 6, 7 and 9 while TLR2, 4 and 8 were not 
detected at all at the RNA level (Fig. 1A). The expression pattern in 293-TLR9 cells was 
similar but they additionally showed strong expression of TLR4 (Fig. 1B), which is usually 
absent in wild type HEK293 cells (Smith et al., 2003). With exception of TLR9, which 
showed a lower expression in 293-TLR9 cells, relative gene expression in 293-TLR9 cells 
was in general higher compared to 293-WT cells. Endogenous TLR9 expression was low in 
both cell lines. These results can be explained by the different origin of the cells or by a clonal 
selection during the establishment of 293-TLR9 cells.  
To confirm ectopical expression of the HA-tagged TLR9 in 293-TLR9 cells we 
performed western blot analysis (Fig. 1C). As expected, we detected strong expression of 
TLR9-HA in 293-TLR9 cells and not in 293-WT. 	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Cytokine response to TLR9 stimulation using synthetic TLR9 ligands in wild type and 
TLR9-engineered HEK293 cells  
Signaling via TLRs ultimately leads to the expression of pro-inflammatory cytokines, 
chemokines and anti-microbial effector molecules (Kawai & Akira, 2011). Cytokines such as 
IL-6 and TNF-α can be used to monitor the response to TLR stimulation in HEK293 cells 
(Assaf et al., 2009; Razonable et al., 2005). We investigated the functionality of TLR9 
signaling in both cell lines upon stimulation of TLR9 with synthetic CpG 
oligodeoxynucleotides (CpGs). We used two different classes of CpGs, class A and B, for 
activation of TLR9 signaling, to determine the most effective stimuli since both classes can 
evoke distinct reactions (Krieg, 2002; Krug et al., 2001; Rothenfusser et al., 2001). We 
measured the changes in IL-6 and TNF-α gene expression in response to TLR9 triggering by 
RT-qPCR and compare it to mock-stimulated cells.  
Upon stimulation with CpG-B, 293-WT cells showed a 4.1-fold (±1.2) increased 
expression of IL-6 compared to mock-stimulated cells after 4h of stimulation. Stimulation 
with CpG-A did not change IL-6 expression significantly (Fig. 2A). TLR9 stimulation in 293-
TLR9 cells did not lead to an IL-6 response at all (Fig. 2B). In contrast, 293-WT cells did not 
show a TNF-α response to TLR9 stimulation (Fig. 2C) while 293-TLR9 cells showed a strong 
induction of 9.8-fold (±0.4) in TNF-α expression 2h post stimulation (Fig. 2D). The 
expression of TNF-α in 293-TLR9 reached a peak after 4h of stimulation with a 18.7-fold 
(±0.01) induction compared to mock-stimulated cells and was still 7.3-fold (±0.1) up-
regulated 6h post stimulation (Fig. 2D). Taken together, both cell lines responded to TLR9 
stimulation with CpG-B but not to CpG-A, while 293-WT cells showed increased IL-6 
expression 4h post stimulation and 293-TLR9 cells responded by strong up-regulation of 
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Figure 1: TLR expression in wild type HEK293 and TLR9-engineered HEK293 cells. TLR1-9 gene 
expression levels were determined in 293-WT (A) and 293-TLR9 (B) cells by RT-qPCR relative to HMBS. Data 
is represented as Mean ±SD of at least 3 independent replicates; n.d. = not detected. C) Ectopical HA-tagged 
TLR9 protein expression was confirmed by western blot. β-Actin served as loading control. 
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TNF-α gene expression. In conclusion, the stimulation with CpG-A is either without effect or 
we might not have chosen the proper readout to detect a response to CpG-A. Additionally, the 
TNF-α response of 293-TLR9 cells appears to be more reliable since it was shown that 
HEK293 cells du not respond to CpG-B stimulation by IL-6 secretion (Assaf et al., 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Continuous TLR9 stimulation and infection by EBV of wild type and TLR9-engineered 
epithelial cells 
Next, we investigated the impact of TLR9 stimulation on the infection susceptibility 
and establishment of persisting infection in both cell lines. Therefore, we activated the 
signaling via TLR9 by stimulation with both types of CpG ODNs, class B and A, 2h prior to 
EBV inoculation and re-stimulated the cells 24h and 48h thereafter. We determined the 
amount of infected cells 72h p.i. by detection of GFP using flow cytometry. 
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Figure 2: Cytokine response in HEK293 cell lines to TLR9 stimulation with synthetic TLR9 ligands. 293-
WT (A; C) and 293-TLR9 (B; D) cells were stimulated with CpG-B (white) or CpG-A (black) and IL-6 (A; B) 
and TNF-α (C; D) gene expression levels were determined as response to TLR9 stimulation by RT-qPCR 
relative to HMBS. Data is represented as fold change of the Mean ±SD to mock stimulated cells of at least 3 
independent experiments; *** = p<0.001; **** = p<0.0001 (ordinary one-way ANOVA; Dunnett’s multiple 
comparison test). 
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293-WT cells showed in general about 3.5-fold higher infection frequencies as 
compared to 293-TLR9 cells. Infection frequencies of mock-stimulated 293-WT cells were 
1.34% (±0.12) while CpG-B and CpG-A stimulation resulted in infection frequencies of 
1.33% (±0.12) and 1.45% (±0.15), respectively. Mock-stimulated 293-TLR9 cells showed 
infection frequencies of 0.32% (±0.00), with CpG-B stimulation of 0.38% (±0.02) and with 
CpG-A stimulation of 0.37% (±0.09). As shown in Figure 3 there was no difference due to 
TLR9 stimulation in 293-WT (Fig. 3A) and in 293-TLR9 (Fig. 3B) cells compared to the 
corresponding mock-stimulated cells. Taken together, we did not observe any impact of TLR9 
stimulation on the infection frequencies of 293-WT and 293-TLR9 cells, nor on the 
persistence of EBV. The lower infection frequencies of 293-TLR9 cells suggest that a clone 
with reduced susceptibility to EBV infection was selected during the establishment of the cell 
line. 
 
 
 
 
 
 
 
 
 
EBV gene expression in wild type and TLR9-engineered epithelial cells upon direct 
infection by EBV with continuous TLR9 stimulation 
Knowing that TLR9 stimulation can drive EBV into latency and inhibit the switch 
from latent to lytic replication (Ladell et al., 2007; Zauner et al., 2010) as well as that 
activation of TLR2 can induce lytic EBV replication (Ueda et al., 2014) we went on to 
determine the impact of TLR9 stimulation on EBV gene expression in epithelial cell lines. 
We determined the expression of the EBV non-coding RNA EBER1, of three latency-
associated genes EBNA1, EBNA2 and LMP1 and of two genes associated with lytic EBV 
mock CpG-B CpG-A
0.0
0.5
1.0
1.5
2.0
Stimulation
%
 G
FP
+ 
ce
lls
 
(fo
ld
 c
ha
ng
e 
ov
er
 
m
oc
k 
st
im
ul
at
io
n)
mock CpG-B CpG-A
0.0
0.5
1.0
1.5
2.0
Stimulation
%
 G
FP
+ 
ce
lls
 
(fo
ld
 c
ha
ng
e 
ov
er
 
m
oc
k 
st
im
ul
at
io
n)
A B 
Figure 3: Infection frequencies of HEK293 cell lines upon direct infection by EBV under continuous 
TLR9 stimulation with synthetic TLR9 ligands. 293-WT (A) and 293-TLR9 (B) cells were stimulated with 
CpG-B (grey) or CpG-A (black) and subjected to direct infection by EBV. Infection frequencies were 
determined 72 h p.i. by flow cytometry within the living cell (7-AAD negative) population and shown as fold 
change over mock stimulated cells (white). Data is represented as Mean ±SD of 3 independent experiments. 
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replication, BZLF1 and BXLF2, in 293-WT (Fig. 4) and in 293-TLR9 (Fig. 5) cells upon 
direct EBV infection and continuous TLR9 stimulation with either CpG-B or CpG-A, as 
mentioned above, in the epithelial model cell lines 293-WT and 293-TLR9. 
In general, consistent with the low infection frequencies we observed low expression 
of all EBV genes including EBER1. In 293-WT cells, the expression of EBER1 was more or 
less constant although it was decreased in mock- and CpG-B-treated samples 48h p.i. (Fig. 
4A). The gene expression of EBNA1, EBNA2 and BXLF2 was decreasing over time in 293-
WT cells (Fig. 4B, C and F), independently of the treatment, while CpG-A treated cells 
showed a slower decrease of EBNA2 and BXLF2 gene expression. LMP1 and BZLF1 gene 
expression hardly reached the limit of detection indicated by the dotted horizontal line, but 
remained relatively constant (Fig. 4D and E). However, when we compared the expression 
levels to mock-stimulated 293-WT cells we did not detect any significant effect on EBV gene 
expression due to treatment with CpG-B and CpG-A, respectively. Taken together, these 
results indicate that neither treatment with CpG-B nor with CpG-A had an affect on EBV 
gene expression in 293-WT cells and thus did not promote EBV latency or EBV persistence. 
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In 293-TLR9 cells we detected even lower gene expression levels as compared to 293-
WT cells, which we expected due to the lower infection frequencies in these cells as 
mentioned above. Additionally, we had to exclude the gene expression data for EBNA1 in 
293-TLR9 from our analysis (Fig. 5B) these cells contain an EBNA1-based expression 
system, which did not allow us to investigate the gene expression of EBNA1 from the viral 
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Figure 4: EBV gene expression in 293-WT cells upon direct infection by EBV under continuous TLR9 
stimulation with CpG-B or CpG-A. Expression of EBER1 (A), EBNA1 (B), EBNA2 (C), LMP1 (D), BZLF1 
(E) and BXLF2 (F) was determined in mock-, CpG-B or CpG-A stimulated 293-WT cells by RT-qPCR relative 
to HMBS. Data is represented as Mean ±SD of 3 independent experiments and tested for statistical significance 
by unpaired t tests to mock-stimulated samples; dotted horizontal line indicates the limit of detection. 
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genome. The expression of EBER1 was slightly increased in mock and CpG-A stimulated 
293-TLR9 cells 48h p.i. and was decreased 72h p.i., while EBER1 expression was not 
affected in CpG-B stimulated cells (Fig. 5A). However, compared to mock-stimulated cells 
the expression of EBER1 remained higher 72h p.i. in CpG-B and CpG-A treated cells. As 
seen in 293-WT cells, the gene expression of EBNA2 and BXLF2 in 293-TLR9 cells was 
decreasing over time in mock- and CpG-B stimulated cells, while CpG-A treated cells showed 
a slight increase in EBNA2 and BXLF2 gene expression 48h p.i. (Fig. 5C and F). Although the 
gene expression levels of EBNA2 and BXLF2 barely reached the limit of detection 72h p.i., 
they were again higher in CpG-B and CpG-A treated cells compared to mock-stimulated cells. 
LMP1 and BZLF1 were, as shown for 293-WT cells, again only weak or even not expressed at 
all in 293-TLR9 cells (Fig. 5D and E). Once again, we did not observe any significant effect 
on EBV gene expression upon treatment with CpG-B and CpG-A, respectively, in 293-TLR9 
cells. Nevertheless, since the expression levels of EBER1, EBNA2 and BXLF2 were still 
higher 72h p.i. in CpG-B and CpG-A treated 293-TLR9 cells compared to mock-stimulated 
cells, these results might imply that TLR9 stimulation could contribute to EBV replication in 
epithelial cells. 	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IX.2.5 Discussion 
EBV is transmitted via saliva and enters the host via the oral mucosal epithelium that 
is per se constantly challenged by various microbes. In this study we employed an epithelial 
cell model to test the influence of TLR9 stimulation on the EBV infection in epithelial cells. 
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Figure 5: EBV gene expression in 293-TLR9 cells upon direct infection by EBV under continuous TLR9 
stimulation with CpG-B or CpG-A. Expression of EBER1 (A), EBNA1 (B), EBNA2 (C), LMP1 (D), BZLF1 
(E) and BXLF2 (F) was determined in mock-, CpG-B or CpG-A stimulated 293-TLR9 cells by RT-qPCR 
relative to HMBS. Data is represented as Mean ±SD of 3 independent experiments and tested for statistical 
significance by unpaired t tests to mock-stimulated samples; n.d. = not detected; dotted horizontal line indicates 
the limit of detection. 
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We found that 1) individual cell lines show a distinct TLR expression pattern; 2) TLR9-
engineered epithelial cells respond to TLR9 stimulation with CpG-B by up-regulation of 
TNF-α gene expression; 3) TLR9 stimulation with CpG-B and CpG-A has no impact on 
infection frequencies of epithelial model cells and does not alter EBV gene expression 
significantly. Our results indicate that the employed epithelial model cell lines 293-WT and 
293-TLR9 may not be physiological models to study the impact of TLR signaling on the 
infection in epithelial cells by EBV, but suggest a contribution of TLR activation to 
reactivation of EBV from latency in epithelial cells. 
Comparing the TLR gene expression pattern in 293-WT and 293-TLR9 cells we found 
obvious differences between distinct cell lines. Both cell lines should originate from the same 
HEK293 cells described by Graham et al. (Graham et al., 1977). Wild type HEK293 cells 
possess functional signaling upon activation of endogenous TLR5 (Huang et al., 2009; Simon 
& Samuel, 2007; Smith et al., 2003) but they do not express TLR2, 4 (Erridge et al., 2007; 
Latz et al., 2002) and TLR6 at protein level (Erridge et al., 2007). It was as well described 
that low levels of TLR9 mRNA can be detected but without functional signaling via TLR9 
(Assaf et al., 2009). Additionally, Assaf et al. detected TLR9 gene expression levels in TLR9-
transfected HEK293 cells comparable to various B-cell lines (Assaf et al., 2009). Since the 
employed primer/probe set, used to amplify a specific fragment within the 5’ untranslated 
region of the TLR9 gene, is specific for endogenous TLR9 and because the expression 
construct for TLR9 within the 293-TLR9 cells contains only the coding region for TLR9, we 
could not detect ectopically expressed TLR9. The strong TLR4 gene expression in 293-TLR9 
cells was unexpected. Functional signaling via TLR4 requires co-expression of MD-2 and 
CD14 (Latz et al., 2002). However, since wild type HEK293 cells are usually deficient for 
both molecules we did not further investigate whether the here measured TLR4 expression 
exhibited functional signaling. The cell line 293-TLR9 was selected from single cell clones, 
showing the best response to TLR9 stimulation, without regard to the overall TLR expression 
pattern (personal communication by the manufacturer). Therefore, we conclude that the 
altered TLR gene expression pattern in 293-TLR9 cells is a result of the clonal selection 
procedure in vitro. 
We determined IL-6 and TNF-α gene expression as response to TLR9 stimulation with 
two distinct classes of synthetic CpGs. To our surprise, 293-WT cells responded to treatment 
with CpG-B with slight up-regulation of IL-6, while 293-TLR9 cells showed a strong TNF-α 
response to CpG-B stimulation. Notably, apart from NF-κB activation and induction of 
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proliferation in TLR9-transfected HEK293 cells, Assaf and colleagues did not observe any 
difference such as increased IL-6 or TNF-α secretion or up-regulation of surface markers in 
control and TLR9-transfected HEK293 cells upon TLR9 stimulation with another class B 
CpG (Assaf et al., 2009). Nevertheless, the strong TNF-α response we observed in 293-TLR9 
cells appears to be more of biological relevance since these cells were shown to be capable of 
NF-κB activation upon TLR9 stimulation (Assaf et al., 2009), which would lead to TNF-α 
expression. To fully confirm functional TLR9 signaling we would additionally need to assess 
secretion of these cytokines. However, as mentioned above, Assaf et al. already demonstrated 
that control and TLR9-engineeried are not capable to secrete IL-6, TNF- α and IL-10 upon 
TLR9 activation. Thus, additionally questioning the biological relevance of these model cell 
lines with respect to the epithelium and the effect of TLR activation on the EBV infection in 
epithelial cells. 
The stimulation with CpG-A had no effect on cytokine expression in 293-WT and 
293-TLR9 cells. Following their distinct structural and biological characteristics, three classes 
of CpG ODNs have been defined (Hartmann et al., 2003; Marshall et al., 2003; Vollmer et 
al., 2004). B-class CpGs strongly activate B cells and have only little effects on induction of 
natural killer (NK) cell activity and interferon-alpha (IFN-α) secretion (Krieg, 2002). On the 
other hand, CpG class A molecules induce a strong NK cell activation and IFN-α secretion 
from plasmacytoid dendritic (pDC) cells, but only weakly stimulate B cells (Krug et al., 2001; 
Rothenfusser et al., 2001). CpG ODNs from class C combine the functional properties from 
class A and B (Hartmann et al., 2003; Vollmer et al., 2004). Although all classes of CpG 
ODNs are sensed by the same TLR9 receptor and CpG-B molecules were frequently used in 
studies especially with airway and intestinal epithelial cells, we might have missed the 
activation upon CpG-A stimulation of the tested cell lines probably due to an inappropriate 
readout. 
We did not observe any significant effect on the infection frequencies or on EBV gene 
expression in 293-WT or 293-TLR9 cells due TLR9 stimulation. Since we recently 
demonstrated that TLR9 stimulation prevents lytic EBV infection upon primary infection of B 
cells and inhibits lytic reactivation in EBV positive BL cells (Ladell et al., 2007; Zauner et 
al., 2010) we hypothesized that TLR9 stimulation might lead to or support the establishment 
of a latent EBV infection as well in epithelial cells. Given that in vitro EBV is rapidly lost 
from epithelial cells (Glaser et al., 1989; Shannon-Lowe et al., 2009; Wu et al., 2003; Yao et 
al., 1990) and that TLR9 stimulation might lead to the establishment of a latent EBV infection 
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in epithelial cells, we expected to be able to measure higher infection frequencies in 293-
TLR9 cells upon TLR9 stimulation. This was not the case, however we detected slightly 
increased expression of EBER1 and EBNA2 and BXLF2 in 293-TLR9 cells upon CpG-B and 
A treatment compared to mock stimulated cells 72h p.i.. Taken into account that we achieved 
only very low infection frequencies (about 0.5% infected 293-TLR9 cells), resulting in very 
low EBV gene expression levels, and that the expression of the late lytic gene BXLF2 was as 
well increased we speculate that TLR9 stimulation in epithelial cells might contribute to lytic 
EBV replication. This is compatible with the finding that TLR2 triggering in EBV positive 
LCLs results in lytic EBV replication (Ueda et al., 2014). 
HEK293 cells and especially the TLR9-engineered HEK293 cells used in this study 
have some limitations. First, these model cell lines show only little relation to epithelial cells 
within the pharyngeal cavities regarding their TLR expression pattern. Especially, TLR2, 3, 4, 
which are not or only weak expressed in HEK293 cells, seem to play a more important role in 
primary epithelial cells and cell lines from the pharyngeal cavities than TLR9 (Claeys et al., 
2003; Lange et al., 2009b; Swaminathan et al., 2013; Tezera et al., 2011; Vandermeer et al., 
2004; Yamada et al., 2011). Second, we could achieve only low infection frequencies in 293-
TLR9 cells probably because of the selection of a cell clone with reduced susceptibility to 
EBV infection during the establishment of the cell line. Third, 293-TLR9 cells were 
established by using an EBV based expression plasmid and therefore constitutively express 
EBNA1 that is essential for episomal plasmid and EBV genome maintenance (Frappier, 2012) 
and will influence EBV gene expression within these cells. It results that the TLR9-
engineered HEK293 cell line itself might not provide a suitable model to study the impact of 
TLR9 or in general TLR signaling on the infection of epithelial cells by EBV. The 
establishment of primary epithelial cell cultures or established cell lines from the pharyngeal 
cavities might provide a considerably more physiological model, thus facilitating the study of 
TLR signaling and its impact on the EBV infection in epithelial cells especially with regard to 
TLRs apart from TLR9. 
Taken together, we show here that activation of TLR9 signaling by synthetic ligands 
in the model cell lines 293-WT and 293-TLR9 does not have a significant impact on EBV 
infection. This does not exclude that EBV might actually benefit from TLR activation within 
the pharyngeal cavities regarding virus transmission. Pharyngeal epithelial cells are in general 
believed to serve as amplifier and to be the source of progeny virus for shedding (Hadinoto et 
al., 2009; Perera et al., 2010). Our observation of a slightly increased EBV gene expression in 
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293-TLR9 cells upon CpG stimulation, especially of the late lytic gene BXLF2, without 
increased infection frequencies, might potentially reflect an ongoing EBV replication. This 
leads us to the hypothesis that activation of TLRs in pharyngeal epithelial cells might serve as 
alarm signal for EBV, triggering lytic replication and therefore ensuring virus transmission 
and spreading to the next naïve host, supported by the recent finding that GAS colonizes 
patients shed higher numbers of EBV particles into saliva (Ueda et al., 2014). 
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